

INFORMATION DISCLOSURE

To: - State Securities Commission

- Hanoi Stock Exchange

1. Name of Organization: **MEDIPLANTEX NATIONAL PHARMACEUTICAL
JOINT STOCK COMPANY**

- Securities code: MED

- Address: 358 Giai Phong, Phuong Liet, Ha Noi

- Person responsible for information disclosure: Mr. Mai Nhat Thanh

Type of disclosed information: Periodic Extraordinary Upon request

2. Contents of disclosure:

- Resolution, Minutes of Meet and documents of the 2026 Annual General Meeting of Shareholders

3. This information was published on the company's website on 30/06/2026, as in the link:
<http://www.mediplantex.com/cổ-đông/công-bố-thông-tin.html>

We hereby certify that the information provided is true and correct and we bear the full responsibility to the law.

**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JSC
GENERAL DIRECTOR**



(Handwritten signature)
Mai Nhat Thanh

DECISION

**Regarding the Establishment of the Shareholder Eligibility Verification Committee
for the 2026 Annual General Meeting of Shareholders**

**THE BOARD OF DIRECTORS OF MEDIPLANTEX NATIONAL
PHARMACEUTICAL JOINT STOCK COMPANY**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, and effective as of January 1, 2021;
- Pursuant to the Charter on the organization and operation of Mediplantex National Pharmaceutical Joint Stock Company, as amended and supplemented for the 12th time on June 26, 2024;
- Based on the proposal of the General Director of the Company.

DECIDES

Article 1. To establish the Shareholder Eligibility Verification Committee to serve the 2026 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company, comprising the following members:

1. Ms. **Do Ngoc Thuy** – Head of the Committee
2. Ms. **Nguyen Thi Hoang Yen** – Member

The Shareholder Eligibility Verification Committee shall automatically dissolve upon completion of its assigned duties.

Article 2. The Committee is tasked with verifying the eligibility of shareholders attending the 2026 Annual General Meeting of Shareholders in accordance with applicable laws and the Company's Charter.

Article 3. This Decision takes effect from the date of signing. The General Director of Mediplantex National Pharmaceutical Joint Stock Company, the Head of the Organizing Committee of the 2026 Annual General Meeting of Shareholders, and the individuals named in Article 1 shall be responsible for implementing this Decision.

Recipients:

- BOD;
- As stated in Article 3;
- Archived: Office.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**



[Signature]

Nguyen Ngoc Xuan Trang

**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JSC**

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

No.: 01/TTr-HĐQT

Hanoi, June 29, 2026

PROPOSAL

**Regarding the Approval of the Vote Counting Committee
for the 2026 Annual General Meeting of Shareholders**

**To: The General Meeting of Shareholders of Mediplantex National Pharmaceutical
Joint Stock Company**

In order to carry out the counting of voting ballots and election ballots at the General Meeting of Shareholders, the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company respectfully proposes to the General Meeting of Shareholders for approval the list of members of the Vote Counting Committee for the 2026 Annual General Meeting of Shareholders as follows:

List of Vote Counting Committee Members:

1. Ms. **Hoang Lan Huong** – Head of the Committee
2. Ms. **Duong Thi Minh Nguyet** – Member

Respectfully proposes to the General Meeting of Shareholders for consideration approval./.

Recipients:

- As stated above;
- BOD, BOS;
- Archived: Office, BOD Office.

ON BEHALF OF THE BOARD OF DIRECTORS



Nguyen Ngoc Xuan Trang

Hanoi, June 29 , 2026

**WORKING AND VOTING REGULATIONS
OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY**

Pursuant to:

- *The Law on Enterprise No. 59/2020/QH14 was passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, amended and supplemented by Law No. 03/2022/QH15 passed by the National Assembly of the Socialist Republic of Vietnam on January 11, 2022, and its implementing guidelines;*
- *The Law on Securities No. 54/2019/QH14, passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, and its implementing guidelines; amended by Law No. 56/2024/QH15, passed by the National Assembly of the Socialist Republic of Vietnam on November 29, 2024, and its implementing guidelines.*
- *The Charter on Organization and Operation issued together with Resolution of the General Meeting of Shareholders No. 01/2024/NQ-GMS/MED dated June 26, 2024 of Mediplantex National Pharmaceutical Joint Stock Company;*
- *The Internal Regulations on Corporate Governance issued together with Resolution of the General Meeting of Shareholders No. 01/2024/NQ-GMS/MED dated June 26, 2024 of Mediplantex National Pharmaceutical Joint Stock Company.*

2026 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company (“MED”, “the Company”) was held and conducted in accordance with the following Working and Voting Regulations:

Article 1. Purpose

- To ensure that the procedures, principles of conduct, and voting at the Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company are carried out in accordance with regulations and in a successful and orderly manner.
- To ensure that the resolutions of the General Meeting of Shareholders reflect the unified will of the General Meeting, safeguard the legitimate rights and interests of

shareholders, and comply with applicable laws.

Article 2. Scope of Regulation and Subjects of Applicable

- **Scope of Regulation:** These Regulations shall apply to the organization of the 2025 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company.
- **Subjects of Application:** All delegates and authorized representatives attending the MED Annual General Meeting of Shareholders must comply with the provisions set forth in these Regulations, the Company's Charter, and the prevailing laws and regulations.

Article 3. Definitions

In these Regulations, the following terms are understood as follows:

1. **Shareholders:** are individuals who own at least one share of Mediplantex National Pharmaceutical Joint Stock Company and whose names are on the list of shareholders entitled to attend the General Meeting of Shareholders on May 28, 2026. Provided by the Vietnam Securities Depository and Clearing Corporation.
2. **The company or MED:** refers to Mediplantex National Pharmaceutical Joint Stock Company.
3. **Delegates are shareholders and/or their (valid) authorized representatives attending the 2026 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company.**
4. **Online General Meeting:** This is a form of organizing a shareholders' general meeting that uses electronic means to transmit images and sound via the internet, allowing shareholders in many different locations to attend the meeting, discuss, and vote on meeting issues.
5. **The online General Meeting venue** includes the main venue and other locations. The main venue is where the Chairperson attends and presides over the meeting, while the other locations are where shareholders log into the EzGSM System using their access accounts provided by MED to participate in the online General Meeting.
6. **Electronic voting:** This refers to shareholders casting votes and elections through the EzGSM system as stipulated in these Regulations.
7. **Electronic means:** are means that operate based on electrical, electronic, digital, magnetic, wireless transmission, optical, electromagnetic or similar technologies.

8. **Online registration for the General Meeting:** This refers to shareholders using their login information to access the system and register to attend the General Meeting online as stipulated in these Regulations and MED 's guidelines.
9. **Login Information:** This includes **the Username and Password** provided by MED to each shareholder in the Meeting Invitation Notice. Shareholders are responsible for keeping their login information and other identifying factors (if any) secure to ensure that only they have the right to use the login information to attend and vote on the system.
10. **Electronic voting system or online General Meeting of Shareholders system:** is a system that supports the organization of the General Meeting of Shareholders, providing delegates with tools to exercise their related rights when attending the General Meeting of Shareholders (including online delegate registration, proxy attendance, online voting and election, etc.);
11. **System Opening Time:** This is the time when shareholders can access, register to attend the online General Meeting, and vote on the items to be voted on at the meeting. The system will close access upon notification from the Chairman or the Organizing Committee of the General Meeting.
12. **Cumulative voting** is a method of cumulative voting where Delegates concentrate their votes on one (01) candidate or divide the votes equally among the maximum number of candidates according to the number of Board of Directors/Supervisory Board members to be elected; After dividing equally, the corresponding number of votes for each candidate is rounded down to the nearest whole number. Any remaining odd votes (if any) will be discarded;
13. **The total number of representative voting ballots** is understood to be the number of ballots with voting rights, including the number of ballots owned by a Delegate and/or authorized by one or more other Delegates;
14. **Total number of votes for board members** This is understood as the total number of representative voting ballots multiplied by the number of elected Board of Directors members.

In these Regulations, the following terms shall have the meanings set out below:

1. "Shareholder" means a person owning at least one share of Mediplantex National Pharmaceutical Joint Stock Company and whose name appears on the list of shareholders entitled to attend the General Meeting of Shareholders, finalized as of May 28, 2026 and provided by the Vietnam Securities Depository and Clearing Corporation (VSDC).

2. "Company" or "MED" means Mediplantex National Pharmaceutical Joint Stock Company.
3. "Delegate" means a shareholder and/or the duly authorized representative of a shareholder attending the 2026 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company.
4. "Virtual General Meeting" means a form of General Meeting of Shareholders conducted through electronic means for the transmission of images and audio via the Internet, enabling shareholders located in different places to attend the Meeting, discuss matters, and exercise their voting rights.
5. "Venue of the Virtual General Meeting" includes the principal venue and other venues. The principal venue is the location where the Chairperson attends and presides over the Meeting, while the other venues are locations where shareholders access the EzGSM System using the login credentials provided by MED in order to attend the Virtual General Meeting.
6. "Electronic Voting" means the exercise by shareholders of their voting rights and election rights through the EzGSM System in accordance with these Regulations.
7. "Electronic Means" means equipment, devices, or methods operating on electrical, electronic, digital, magnetic, wireless transmission, optical, electromagnetic, or similar technologies.
8. "Registration for Attendance at the Virtual General Meeting" means the use by a shareholder of the Login Credentials to access the system and register for attendance at the Virtual General Meeting in accordance with these Regulations and the instructions issued by MED.
9. "Login Credentials" include a Username and Password uniquely provided by MED to each shareholder in the Meeting Invitation Notice. Shareholders are responsible for maintaining the confidentiality of their Login Credentials and any other identification factors (if any) to ensure that only the shareholder is entitled to use such credentials to attend and vote through the system.
10. "Electronic Voting System" or "Online General Meeting System" means the system supporting the organization of the General Meeting of Shareholders and providing Delegates with tools to exercise their rights in connection with attendance at the General Meeting of Shareholders, including online registration, proxy appointment, electronic voting, and online election procedures.
11. "System Opening Time" means the time from which shareholders may access the system, register for attendance at the Virtual General Meeting, and vote on matters submitted for approval at the Meeting. Access to the system shall be closed in

accordance with the announcement of the Chairperson or the Organizing Committee of the Meeting.

12. "Equal Distribution of Cumulative Votes" means a method of cumulative voting whereby Delegates may allocate all of their votes to one (01) candidate or distribute their votes equally among a number of candidates not exceeding the number of members of the Board of Directors or the Supervisory Board to be elected. Following such distribution, the number of votes allocated to each candidate shall be rounded down to the nearest whole number. Any remaining fractional votes shall be disregarded.
13. "Total Number of Represented Voting Rights" means the total number of voting rights represented by a Delegate, including voting rights attached to shares owned by the Delegate and/or voting rights validly authorized by one or more other Delegates.
14. "Total Number of Votes for the Election of Members of the Board of Directors" means the Total Number of Represented Voting Rights multiplied by (x) the number of members of the Board of Directors to be elected.

Article 4. Conditions and procedures for conducting the General Meeting of Shareholders (*According to the Company's Charter*)

1. The General Meeting of Shareholders (GMS) shall be convened when the attending shareholders represent more than 50% of the total voting shares.
2. In the event that the required number of shareholders is not present within thirty (30) minutes from the scheduled opening time of the meeting, a second meeting invitation must be issued within thirty (30) days from the intended date of the first GMS. The reconvened GMS shall only be conducted if the attending shareholders and authorized representatives represent at least 33% of the total voting shares.
3. If the second meeting cannot be held due to the absence of the required number of attendees within thirty (30) minutes from the scheduled start, a third meeting invitation must be issued within twenty (20) days from the intended date of the second GMS. In this case, the GMS shall be convened regardless of the number of shareholders or authorized representatives in attendance and shall be deemed valid, with the authority to decide on all matters originally proposed for approval at the first GMS.
4. The system for organizing online meeting and electronic voting must meet the following conditions:
 - The system must be maintained to operate safely and stably, ready to meet the connectivity and participation requirements of shareholders.
 - The main venue must ensure adequate sound, lighting, internet connection, power

supply, electronic equipment, and other facilities as required by the nature of the online meeting.

- Ensure information security and maintain the confidentiality of access accounts to the System. All information received and provided on the System must adhere to information security principles and comply with the regulations of the Law on Cybersecurity.
- Electronic data from the online conference program must be recorded, stored, and used in accordance with regulations.

Article 5. Registration for Attendance at the Online General Meeting of Shareholders

1. Participants:

Shareholders of MED holding voting shares (according to the list of shareholders finalized on the record date of May 28, 2026) shall have the right to attend the General Meeting of Shareholders in person or authorize their representatives to attend on their behalf. Where a shareholder is an individual, he/she may authorize only one other individual to attend the Meeting on his/her behalf. Where a shareholder is an organization entitled under applicable laws to appoint more than one authorized representative to attend the Meeting, the number of shares and voting rights represented by each authorized representative must be clearly specified. An authorized representative who has been authorized to attend the Meeting may not further delegate such authority to a third party.

2. Technology requirements:

Delegates shall attend the Online General Meeting of Shareholders and conduct electronic voting through the website: med.ezgsm.fpts.com.vn. Delegates attending the Online General Meeting of Shareholders must have an electronic device with Internet access to ensure their ability to follow the proceedings of the Meeting and participate in electronic voting, including but not limited to computers, mobile phones, tablets, and other Internet-enabled electronic devices.

3. Method of Attendance:

- For shareholders:

Each shareholder listed in the register of shareholders entitled to attend the 2026 Annual General Meeting of Shareholders as of May 28, 2026 shall be provided with one (01) unique username and one (01) corresponding password for access to the General Meeting and participation in electronic voting.

Such username and password shall be provided to each shareholder together with the Notice of Invitation to the General Meeting of Shareholders. Upon receipt of the Notice containing information relating to the access account, shareholders shall be responsible for maintaining the confidentiality of such information to ensure that only the shareholder may access and vote through the Electronic Voting System.

The Company recommends that, upon receipt of the login credentials, including at minimum the username and password, shareholders promptly access the system and change their password in order to enhance account security.

A shareholder who registers to attend the Online General Meeting after the Meeting has officially commenced may still register and shall be entitled to vote and participate in elections upon completion of the registration process. The Chairperson shall not be required to suspend the Meeting, and the validity of any voting conducted prior to such registration shall remain unaffected.

- For authorized representatives of shareholders:

Shareholders and authorized representatives of organizational shareholders may attend the Meeting directly or authorize one or more individuals or organizations to attend the Online General Meeting and participate in electronic voting on their behalf.

Such authorization must be made in writing. The power of attorney shall be prepared in accordance with applicable civil laws and must clearly specify the name of the authorizing shareholder; the name of the authorized individual or organization; the number of shares represented; the scope and content of authorization; the term of authorization; and the signatures of both the authorizing party and the authorized party.

The individual or organization authorized to attend the General Meeting of Shareholders must submit the original valid power of attorney to the Company no later than 3:00 p.m. on June 24, 2026 so that the Company may provide login credentials for access to the Online General Meeting System.

Where the authorized representative is not a shareholder of MED, upon receipt of a duly executed authorization document from both the authorizing party and the authorized party, MED shall provide a username and password to the authorized representative, enabling him/her to exercise the rights and perform the obligations delegated under the authorization.

Mediplantex National Pharmaceutical Joint Stock Company shall provide login credentials to the authorized representative via email or by other means based on the registration information provided by the shareholder. The shareholder shall bear full

responsibility for the authorization information submitted to MED.

Where the authorized representative is also a shareholder of the Company, such representative shall use his/her own access account (as stated in the Company's Notice of Invitation) to attend the Meeting and exercise the voting rights authorized by the shareholder at the General Meeting of Shareholders.

- **Revocation of Authorization:**

A shareholder may revoke an authorization by submitting an official written notice of revocation to the Company prior to the official commencement of the Meeting.

The effective time of such revocation shall be determined based on the time at which the Company receives the written notice of revocation.

A revocation of authorization shall not be effective if the authorized representative has successfully completed online attendance registration through the Electronic Voting System in accordance with Article 6 of these Regulations or has already cast a vote on any matter included in the agenda of the General Meeting of Shareholders.

4. Reissuance of Login Credentials.

Where a shareholder requests the reissuance of login credentials, the Organizing Committee may require the shareholder to provide personal identification information, including at a minimum: For individual shareholders: Citizen Identification Card/Passport number, mobile phone number, email address, and permanent or temporary residential address (or correspondence address); For organizational shareholders: Enterprise Registration Certificate number, contact telephone number, and registered head office address. The Company may resend the username and password to the shareholder via email or by other means based on the registration information provided by the shareholder, enabling the shareholder to attend and vote at the Meeting..

Article 6. Method of recording the attendance of delegates at the online General Meeting of Shareholders

1. Delegates are considered to have attended the General Meeting online from the moment they successfully register to attend the meeting online through the Electronic Voting System, as per the Guidelines for Attending the 2026 Annual General Meeting of Shareholders posted on the Company's website.
2. Delegates are considered to have participated in the online Congress validly and fully when they do so in one of the following ways:
 - Attending the Online Congress: I have logged in and registered to attend the meeting

on the online congress system via the following link : med.ezgsm.fpts.com.vn , using the username and password provided by the Company during the General Meeting until the end of the voting period.

- In the event that a delegate has logged in and registered to attend but does not vote by the time of voting, the shareholder will still be considered to have attended the General Meeting and will be deemed to have not voted, in accordance with the procedures, content of the meeting, voting results, and meeting minutes.

Article 7. Rights and obligations of delegates when attending the online General Meeting of Shareholders

1. Attend the General Meeting online and vote on all matters of the General Meeting as stipulated in the Charter of Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company, this Regulation, and the guidelines on the company's website.
2. Have the right to express their opinions and participate in discussions at the Congress as stipulated in Article 12 of these Regulations.
3. Comply with the instructions of the Chairperson and refrain from causing disruption or disorder during the Congress.
4. Delegates must prepare and use appropriate online meeting equipment with an internet connection to ensure they can follow the proceedings of the online Congress.
5. All electronic voting results of delegates are considered to reflect the will of the delegates. Voting results obtained electronically have the same legal validity as voting at a face-to-face congress.
6. Delegates may use the login information provided by MED to access, participate in, and electronically vote on all voting and election matters of the Congress. Delegates are responsible and have no right to complain if they leave the system for any reason or allow others to use their login information to access the system during the Congress, from the time the system opens for registration, discussion, and voting until it closes.
7. Delegates are responsible for keeping their login information secure to ensure that only shareholders have the right to attend and vote electronically on the system. The company will provide maximum support in ensuring delegates can attend and vote at the General Meeting of Shareholders, but will not be responsible for any issues arising from shareholders losing their login information. In the case of proxy attendance, both the shareholder and the authorized person are responsible for the authorization and the results of electronic voting based on the provided login information.

8. In cases where delegates, after registering to attend the online General Meeting, are unable to participate continuously until the end of the program, they may vote on matters requiring shareholder approval before logging out of the system.

Article 8. Chairperson

1. The Chairman of the Board of Directors or a member of the Board of Directors authorized by the Chairman of the Board of Directors shall be the Chairperson of the 2026 Annual General Meeting of Shareholders of MED.
2. In case the Chairperson is absent or temporarily unable to perform duties, the remaining members shall elect one among themselves to act as the Chairperson of the meeting according to the majority rule. In the event that no Chairperson is elected, the Head of the Board of Supervisors shall preside over the process for the General Meeting of Shareholders to elect a Chairperson of the meeting, and the person who receives the highest number of votes shall act as the Chairperson of the meeting
3. Duties of the Chairperson:
 - a. To preside over the activities of the General Meeting of Shareholders in accordance with the Agenda proposed by the Board of Directors and approved by the General Meeting;
 - b. To guide the Delegates and the Meeting in discussing the matters included in the agenda;
 - c. To present draft resolutions and provide conclusions on necessary issues for the General Meeting to vote on;
 - d. To respond to matters requested by the General Meeting;
 - e. To address any issues arising during the course of the Meeting.

Article 9. Secretariat of the General Meeting

1. The Secretariat of the General Meeting is nominated by the Chairperson (through the General Meeting Organizing Committee); is responsible to the Chairperson and the General Meeting of Shareholders for their duties and operate under the direction of the Chairperson.
2. The Secretariat's responsibilities:
 - a. Assist the Chairperson in verifying the credentials of delegates attending the meeting (when necessary);
 - b. Assist the Chairperson in announcing draft documents, conclusions, and resolutions

of the Congress, and send notifications from the Chairperson to delegates when requested;

- c. Compile the opinions of shareholders during the online General Meeting and submit them to the Chairperson;
- d. Record fully and truthfully the entire content and proceedings of the Congress, as well as the issues that were approved or are still being considered, in the Congress Minutes;
- e. Prepare meeting minutes and draft resolutions on issues adopted at the Congress;
- f. Assist the Chairperson in announcing information related to the General Meeting of Shareholders and notifying the Shareholders' Delegates in accordance with legal regulations and the Company's Articles of Association.

Article 10. Delegate Eligibility Verification Committee

1. The Delegate Eligibility Verification Committee of the General Meeting shall consist of two (02) members, including one (01) Head of the Committee and one (01) member. The Committee shall be established by the Board of Directors and introduced to the General Meeting by the Chairperson. The Delegate Eligibility Verification Committee shall be accountable to the Chairperson and the General Meeting of Shareholders for the performance of its duties.
2. Duties of the Delegate Eligibility Verification Committee:
 - a. To examine and verify the eligibility of Delegates registering to attend the Online General Meeting in accordance with applicable laws, the Company's Charter on Organization and Operation, and these Regulations.
 - b. To report to the Online General Meeting on the percentage of attending Delegates. The Delegate Eligibility Verification Committee shall rely on the login information associated with the Delegates' access accounts as the basis for determining attendance at the Online General Meeting.
 - c. If the Meeting is attended by Delegates representing more than fifty percent (50%) of the total voting shares, the General Meeting of Shareholders of MED shall be duly convened and entitled to proceed.

Article 11. Vote Counting Committee

1. The Vote Counting Committee of the General Meeting shall consist of 02 members, including 01 Head and 01 members, who are nominated by the Chairperson (through the Meeting Organizing Committee) and approved by the General Meeting.



2. Duties of the Vote Counting Committee:

- a. Disseminate the principles, regulations, and guidelines on the voting procedures;
- b. Verify and record voting cards, prepare vote counting minutes, announce results; submit the minutes to the Chairperson for approval of voting and election results;
- c. Promptly notify the Meeting Secretary of the voting results;
- d. Review and report to the General Meeting any violations of voting regulations or complaints regarding the voting results;
- e. Prepare the vote counting minutes and be accountable to the Chairperson and the General Meeting of Shareholders in the performance of their duties.

Article 12. Discussion at the General Meeting

1. Principle:

- a. Discussions will only be conducted within the stipulated time and will be limited to the issues presented in the agenda of the Shareholders' General Meeting;
- b. Shareholders conduct discussions as instructed by the Chairperson during the online General Meeting;
- c. Shareholders can participate in discussions at the online General Meeting by submitting their opinions through the direct connection methods guided by the company on the company website. The Secretariat is responsible for compiling the shareholders' opinions and sending them to the Presiding Board, while also recording the shareholder's name, shareholder code (if any), and the content of the question;

2. Responding to the delegates' questions:

- a. Based on the discussion comments submitted by the delegates, the Chairperson or a member designated by the Chairperson will address the delegates' comments.
- b. In case of time constraints, questions that were not answered directly at the General Meeting will be answered by the company to shareholders through appropriate means.

Article 13. Voting on Matters Submitted to the General Meeting

1. Voting period

- a. Shareholders may cast their votes from the time the voting function becomes active on the System (at least one (01) day prior to the official opening of the General Meeting) until the voting period is declared closed by the Chairperson of the Meeting. Where a shareholder has already cast a vote but wishes to change his/her voting decision, such change must be made before the voting period closes. The last

voting instruction recorded by the System before the closing of the voting period shall be deemed valid and shall be included in the vote-counting results.

- b. Prior to the closing of the voting period, shareholders may only view their own voting results. Upon the closing of the voting period, the overall voting results for each agenda item shall be announced by the Chairperson or the Vote Counting Committee.

2. Voting method

- a. Shareholders shall use the Login Information provided by the Company in the Notice of Invitation to access the System at <https://med.ezgsm.fpts.com.vn> in accordance with the instructions published on the Company's website at <https://www.mediplantex.com> and cast their votes electronically
- b. For each matter submitted for approval, a Delegate shall select one (01) of the following voting options: “**Approve**”, “**Disapprove**”, or “**Abstain**”, and then click the “**Vote**” button to save and submit the voting result to the System. Before the voting period closes, a Delegate may change his/her voting decision by selecting another voting option and clicking the “**Change Vote**” button to confirm the final voting instruction. If a Delegate fails to click the confirmation button to submit the vote through the Electronic Voting System before the voting period closes, such voting card shall be deemed not returned in respect of the relevant agenda item. Where a Delegate does not select any voting option, such Delegate shall be deemed to have declined to exercise his/her voting right and not to have participated in voting on that matter. The corresponding voting rights shall not be included in the total number of votes participating in the voting for that matter.
- c. Depending on the proceedings and agenda of the General Meeting, voting on matters submitted to the General Meeting may be conducted in multiple voting rounds. Shareholders attending the Online General Meeting shall comply with the voting period applicable to each voting round as announced by the Chairperson and notified through the Electronic Voting System. Shareholders shall cast votes on all matters included in the same voting round.
- d. An invalid voting card is a voting card containing one or more agenda items on which no voting opinion has been indicated by the Delegate. The Electronic Voting System shall issue a warning in the event of an invalid voting card. Shareholders shall be responsible for correcting and resubmitting a valid voting card. Invalid voting cards

shall not be recorded by the System, and the relevant shareholder shall be deemed present but not to have voted on the relevant matter (i.e., a non-returned vote).

- e. A Delegate may change his/her voting result multiple times but may not revoke a vote once cast. The Electronic Voting System shall only recognize the final voting instruction recorded at the time the voting period closes for each voting round as determined by the Chairperson. The voting results for each agenda item shall be reported to the General Meeting by the Vote Counting Committee immediately after completion of the vote-counting process.
- f. During the conduct of the General Meeting, the Chairperson shall announce the closing time of voting on the System so that shareholders may exercise their rights accordingly. Where a shareholder encounters technical difficulties in casting votes through the System, such shareholder may contact the hotline announced by the Organizing Committee for guidance and assistance. Upon closure of voting for a particular matter on the System, shareholders shall no longer be entitled to cast votes or modify any voting instruction relating to that matter. The voting results recorded by the System based on the shareholder's Login Credentials shall be deemed final and conclusive, and no complaint, dispute, or legal action relating thereto shall be accepted.

3. Voting rules:

- a. Each share owned or represented shall carry one (01) vote.
- b. Pursuant to Clause 1, Article 21 of the Company's Charter, resolutions on the following matters shall be approved if they receive affirmative votes representing at least sixty-five percent (65%) of the total voting rights of all shareholders attending and voting at the General Meeting:
 - Amendments and supplements to the Company's Charter;
 - Types of shares and the total number of shares to be offered for sale;
 - Merger, reorganization, or dissolution of the Company;
 - Investments or transactions involving the sale of assets with a value equal to or exceeding thirty-five percent (35%) of the total assets recorded in the Company's most recently audited financial statements;
 - Changes to the Company's business lines, industries, or business sectors.
- c. Except for the matters specified above, all other resolutions shall be approved if they receive affirmative votes representing more than fifty percent (50%) of the total voting rights of all shareholders attending and voting at the General Meeting, except in cases

otherwise provided for in Clause 1, Article 21 of the Company's Charter and Clauses 3, 4, and 6 of Article 148 of the Law on Enterprises.

4. Vote Counting Method and Voting Results

- a. The vote counting committee, approved by the General Meeting of Shareholders, is responsible for verifying the results of the electronic voting to compile the final voting results.
- b. The electronic voting system records the number of ballots issued, the number of ballots received, the number of ballots not received, and the percentage of the total votes cast by all shareholders attending and voting at the meeting.
- c. All ballots received and recorded by the electronic voting system are valid.
- d. Each delegate's vote is recorded by the system as follows: the number of votes in favor, the number of votes against, and the number of abstentions.
- e. The voting results are announced by the Chairperson or the Vote Counting Committee immediately at the online Congress.

Article 15. Election of additional members to the Board of Directors

1. Election method:

The voting for the election of additional members to the Board of Directors for the 2024-2029 term will be conducted using the cumulative voting method. Accordingly:

- Each delegate has a total number of votes corresponding to the total number of shares they represent multiplied by the number of additional members elected to the Board of Directors for the 2024-2029 term.
- Delegates may allocate all or part of their total votes to one or more individuals, but not exceeding the number of members approved by the General Meeting of Shareholders.
- The elected members of the Board of Directors are determined by the number of votes received, from highest to lowest, starting with the candidate with the highest number of votes until the required number of members is elected. If two or more candidates receive the same number of votes, a re-election will be held among those candidates, or a selection will be made based on other criteria approved by the General Meeting of Shareholders.

2. Election Ballot:

Each ballot for the election of members of the Board of Directors may be used to elect up to the maximum number of Board members to be elected, as approved by the General Meeting of Shareholders.

18
i T
HÁ
NG
AN
HỒ

Each ballot for electing board members has two columns: "Cumulative voting" and "Number of votes". Shareholders should cast their votes according to the following instructions:

Case 1: If the Delegate casts all their votes for one person (01) candidate

Delegates should check the box in the "Allocate votes equally" column for the respective selected candidates.

Case 2: If the delegate does not vote for any candidate.

Delegates should leave the "Equally Selected" and "Number of Votes" columns blank, **and NOT** mark any symbols for all candidates.

3. Online Election Procedure:

The election voting period shall commence when the Electronic Voting System is activated and shall continue until the Chairperson of the General Meeting or the Vote Counting Committee announces the close of the election voting period. Delegates who exercise their voting rights from the time the Electronic Voting System is activated shall be counted as attending the Online General Meeting of Shareholders.

After completing the election ballot, the Delegate shall click the "Vote" button to save and submit the election results to the System. Delegates may amend their election votes at any time before the close of the election voting period as directed by the Chairperson; however, they may not withdraw their election votes. The election results recorded by the System at the close of the voting period shall be deemed the final and valid election results of the Delegate. Upon the expiration of the election voting period, the System shall no longer accept or record any additional electronic election votes submitted by Delegates.

4. Validity of ballots

For invalid ballots, the electronic voting system will send a warning to delegates attending the online General Meeting of Shareholders and those who cast their votes electronically. Delegates are responsible for correcting their ballots to make them valid. The system will not record invalid ballots, and delegates will be considered as not having participated in the election through the electronic voting system.

Article 16. Minutes of Meeting, Resolutions of the General Meeting of Shareholders

The minutes and resolutions of the General Meeting of Shareholders must be read and approved before the closing of the meeting.

Article 17. Implementation of the Regulations

130
Y
N
UD
ITEX
HA

Delegates and guests attending the General Meeting must strictly comply with these Working and Voting Regulations, the company's current regulations, internal rules, and governance regulations, and relevant legal provisions. Delegates who violate these Rules will be subject to disciplinary action by the Chairperson, depending on the severity of the violation, in accordance with the Company Charter and the Law on Enterprises.

These regulations consist of 17 articles and will take effect immediately after being approved by the Company's 2026 Annual General Meeting of Shareholders.

OB. BOARD OF DIRECTORS

CHAIRMAN 



Nguyen Ngoc Xuan Trang





CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Phường Phương Liệt - Hà Nội

Website: <http://www.mediplantex.com>

No. 01/2026/BC-MED

Hanoi, June 29, 2026

REPORT OF THE BOARD OF DIRECTORS ON THE 2025 PERFORMANCE AND THE PROPOSED OPERATIONAL PLAN FOR 2026

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly of the Socialist Republic of Vietnam on January 11, 2022;
- Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company;

The Board of Directors for the 2024–2029 term of Mediplantex National Pharmaceutical Joint Stock Company respectfully submits to the Annual General Meeting of Shareholders the Report of the Board of Directors on our performance in 2025 and the proposed operational plan for 2026 with the following main contents:

I. 2025 PERFORMANCE RESULTS

1. Board of Directors Personnel Structure

No.	Member	Position	Date of Commencement/Termination as BOD Member/Independent BOD Member	
			Date of appointment	Date of dismissal
1	Nguyen Ngoc Xuan Trang	BOD Chairman	30/06/2025	
2	Tran Nguyen Hoang Phuc	BOD Member	30/06/2025	
3	Tran Nguyen Hoang An	BOD Member	26/06/2024	
4	Nguyen Thi Thuy	BOD Member	26/06/2024	
5	Thai Khac Minh	BOD Independent member	26/06/2024	
6	Tran Hoang Dung	BOD Chairman		Deceased on 30/06/2025
7	Tran Xuan Dinh	BOD Member		30/06/2025

The composition of the BOD ensures a balanced structure among executive members, non-executive members, and independent members in accordance with the Company's Charter and the Internal Corporate Governance Regulations.

2. Resolutions/Decisions of the Board of Directors

In 2025, the Board of Directors held four (04) meetings in accordance with applicable laws and the Company's Charter to review, discuss, and decide on matters within its authority. On this basis, the Board of Directors issued thirteen (13) resolutions to implement governance, management, and operational direction for the Company.

The meetings of the Board of Directors were conducted in full compliance with the prescribed procedures and formalities. All members of the Board of Directors attended the meetings and actively contributed their opinions on the matters under consideration and decision-making. The Board of Supervisors attended the meetings in accordance with its statutory functions to perform supervisory duties and coordinate in corporate governance activities.

3. Activities of the Board of Directors

In 2025, the Board of Directors conducted periodic meetings and adopted written resolutions in accordance with the Law on Enterprises, the Company's Charter, and relevant legal regulations. The matters discussed at these meetings focused on issues within the authority of the Board of Directors, including corporate governance, business and production orientation, organizational restructuring, risk control, and other key matters of the Company. All members of the Board of Directors fully attended the meetings, and the Board of Directors issued timely directives, thereby contributing to the effective implementation of the targets set out in the resolutions of the General Meeting of Shareholders.

The Board of Directors regularly supervised the activities of the Board of Management in implementing business and production plans, financial management, investment activities, human resource management, and compliance with information disclosure obligations applicable to a public listed company.

Key matters reviewed, decided, and supervised by the Board of Directors during the year include:

- Issuance of a resolution appointing Mr. Mai Nhat Thanh as General Director, effective from January 2, 2025, in accordance with its authority and applicable legal regulations.

- Assignment of duties among members of the Board of Directors and election of Ms. Nguyen Ngoc Xuan Trang as Chairwoman of the Board of Directors, effective from June 30, 2025, in accordance with the Company's Charter and relevant legal regulations. Review and approval of amendments and supplements to the internal spending regulations to strengthen corporate governance, enhance management, supervision, and control of executive activities, thereby minimizing risks in production and business operations.

- Supervision of the Board of Management in implementing solutions to improve capital efficiency, cost management, receivables control, financial safety, and overall business performance, as well as operational and professional activities, in order to minimize professional errors in the Company's operations.

- Direction and supervision of the implementation of full, transparent, and timely information disclosure in accordance with securities laws and regulations of the Hanoi Stock Exchange.

4. Supervision Results of the Board of Directors over the General Director

In 2025, the Board of Directors exercised its supervisory function over the General Director and the Board of Management through periodic reports, specialized reports, Board meetings, and internal control mechanisms in accordance with applicable laws, the Company's Charter, and the Internal Governance Regulations. The Board of Directors promptly addressed issues arising within its authority.

The Board of Directors regularly reviewed and assessed the implementation of resolutions of the General Meeting of Shareholders and the Board of Directors, as well as the Company's business performance, financial position, investment activities, risk management, human resource management, and other governance and operational matters under the responsibility of the Board of Management. It also timely considered and decided on matters within its authority to ensure that the Company's operations were conducted in a stable, efficient manner and aligned with the approved development orientation.

Based on the supervisory results, the Board of Directors assessed that the General Director and the Board of Management fulfilled their assigned duties and responsibilities in accordance with applicable laws, the Company's Charter, resolutions of the General Meeting of Shareholders, and resolutions and decisions of the Board of Directors, as follows:

- The Board of Management fully complied with periodic and ad hoc reporting requirements as requested by the Board of Directors and the Chairman of the Board of Directors; and promptly provided information and proposed solutions for arising issues during operations for the Board of Directors' consideration and decision-making within its authority.

- Successfully organized the 2025 Annual General Meeting of Shareholders on June 30, 2025 in accordance with applicable laws, the Company's Charter, and relevant regulations.

- Effectively implemented key tasks and solutions in 2025 under the direction of the Board of Directors:

+ The Board of Management demonstrated proactive and flexible operational management, issuing decisions within the authority of the General Director to

enhance governance efficiency and control of production and business activities. In 2025, revenue reached VND 366.8 billion, exceeding the annual plan by 22%, while profit before tax reached VND 20.6 billion, exceeding the plan by 60% and increasing by 6% compared to 2024.

- + Strengthened receivables management and debt collection, particularly overdue receivables. Cash flow management was improved to optimize financial costs and reduce bank interest expenses.
- + Strengthened control over production costs and administrative expenses. Investment and procurement activities were carried out in strict compliance with the Company's internal regulations and applicable laws.
- + Invested in an additional HPLC system to enhance testing capacity and product research and development, serving quality control of raw materials, semi-finished products, and finished products, while meeting research, validation, and quality management standards under current GMP requirements.
- + Strictly complied with reporting obligations and ensured complete, transparent, and timely information disclosure in accordance with regulations of the Stock Exchange and the State Securities Commission of Vietnam.

Based on the results achieved in 2025, the Board of Directors acknowledges the efforts of the General Director and the Board of Management in maintaining stable production and business operations, achieving and exceeding key performance targets, and ensuring compliance with applicable laws and the Company's internal regulations.

5. Evaluation Results from the Independent Member on the Activities of the Board of Directors

As of December 31, 2025, the Company's Board of Directors has one (01) independent member.

- In 2025, the independent member of the Board of Directors participated in 100% of in-person meetings and written resolutions of the Board of Directors, and provided opinions, feedback, and recommendations on matters within the Board's authority for consideration and decision-making. Based on monitoring and participation in the Board's activities during 2025, the independent member provides the following assessment:

- Meetings of the Board of Directors were convened, organized, and conducted in full compliance with the procedures prescribed under the Law on Enterprises, the Company's Charter, and the Internal Regulations on Corporate Governance. Meeting materials were properly prepared and provided to members of the Board of Directors in accordance with regulations to support review, discussion, and voting.

- The Board of Directors has exercised its rights and fulfilled its duties in accordance Report of BOD on its performance in 2025 and the proposed operational plan for 2026

with applicable laws and the Company's Charter. Resolutions and decisions of the Board of Directors were made based on submitted dossiers and documents, discussion outcomes, and assessments of relevant factors affecting the Company's operations.

- Strategic directions, development orientations, business plans, and key policies were considered and approved by the Board of Directors in alignment with resolutions of the General Meeting of Shareholders, the Company's actual operational situation, and corporate governance requirements.

- The Board of Directors exercised its supervisory function over the General Director and the Board of Management through reporting, inspection, and periodic evaluation mechanisms; and paid attention to risk management, internal control, and legal compliance in the Company's operations. The Board of Directors has completed its assigned duties with a high level of responsibility and professionalism, in full compliance with applicable laws, the Company's Charter, and ethical standards in business conduct.

Based on the above, the independent member of the Board of Directors assesses that the Board of Directors has fully performed its functions, duties, and authority in accordance with regulations, and has effectively maintained governance, supervision, and strategic direction for the Company in 2025.

6. Remuneration and Salary Payment for the Board of Directors

The salary and remuneration for the Board of Directors were paid in accordance with the resolution of the 2025 Annual General Meeting of Shareholders (*The figures are reflected in the audited 2025 financial statements*).

7. Transactions with Related Parties

No.	Name	Related Party Relationship	NSH No. / Issue Date / Place of Issue	Head Office Address	Transaction Time
1	An Hy Pharmaceutical Company Limited	Related Party of Ms. Nguyen Ngoc Xuan Trang – Chairman of the Board of Directors	Enterprise Registration Certificate No. 0309738339, issued on May 22, 2017 by the Department of Planning and Investment of Ho Chi Minh City	No. 506/15/34, 3/2 Street, Ward 14, District 10, Ho Chi Minh City	2025

II. ORIENTATION AND OPERATION PLAN FOR 2026

1. The Board of Directors will continue to maintain quarterly periodic meetings in accordance with regulations, and extraordinary meetings when necessary in compliance with applicable laws, the Company's Charter, and the Internal Regulations on Corporate Governance. The Board will also adopt written resolutions on matters within its authority

in order to implement the resolutions of the 2026 Annual General Meeting of Shareholders and perform the Company's governance responsibilities.

2. To continue improving corporate governance quality toward greater transparency, efficiency, and alignment with advanced governance practices; to strengthen supervision over the implementation of production and business targets, financial management, risk management, receivables management, capital utilization, and investment efficiency, thereby ensuring financial safety and sustainable development of the Company.
3. To provide orientation and supervision to the Board of Management in implementing solutions to strengthen production capacity and improve operational efficiency of manufacturing plants; to focus on developing strategic products, enhancing competitiveness, and optimizing the utilization of production resources.
4. To review and decide on investment policies, research and development activities, and product registration within its authority; to facilitate the Board of Management in promoting R&D activities, expanding the product portfolio, improving production capacity, and enhancing the Company's market competitiveness. Priority shall be given to high value-added products with strong research content and sustainable growth potential, while also reviewing and restructuring the product portfolio in line with the Company's development strategy and market trends.
5. To continue promoting digital transformation in corporate governance and business operations; to strengthen the application of information technology in management, internal control, and operational activities; and to gradually explore the adoption of artificial intelligence (AI) solutions appropriate to actual conditions in order to improve governance efficiency and productivity. Based on the assessment of the Company's 2025 performance, existing production capacity, development orientation, and market factors, the Board of Directors hereby submits the 2026 business plan to the General Meeting of Shareholders for consideration and approval as follows:

No	Indicator	Actual 2025	Plan 2026	2026 Plan / 2025 Actual (%)
1	Total Revenue	366,830	412,071	112%
2	Cost of Goods Sold	281,043	321,273	114%
3	Gross Profit	85,787	90,797	106%
4	Selling Expenses	4,734	4,949	105%
5	Administrative Expenses	58,627	62,822	107%
6	Profit Before Tax	20,659	15,005	73%

The 2026 profit plan has been prepared on a prudent basis, reflecting the Company's strategic direction to increase investment in research and development activities, new product registration, expansion of production capacity, digital transformation, and taking into account volatility factors in the pharmaceutical market. The Board of Directors will regularly monitor actual developments in order to implement appropriate management solutions to strive for the completion and potential overachievement of the targets approved by the General Meeting of Shareholders.

The above is the report of the Board of Directors on the assessment of the Board's performance in 2025 and the operational direction for 2026. The Board of Directors acknowledges and highly appreciates the efforts of the Board of Management and all employees in maintaining stable business operations in 2025. The achieved results serve as an important foundation for the Company to further strengthen its internal capacity, enhance governance capability, and move toward stable and sustainable development in the next stage.

On behalf of the Board of Directors, I would like to extend my sincere appreciation to the Board of Management and all employees for their continuous efforts and contributions to the development and success of Mediplantex.

Sincere thanks are also extended to our shareholders, investors, customers, and partners for their continued trust and support in Mediplantex's journey toward stable, sustainable, and efficient development.

Sincerely!

Recipients:

- BOD
- BOM
- Shareholders
- State Securities Commission
- Archived: Company Secretary

OB. THE BOARD OF DIRECTORS
CHAIRMAN 



Nguyen Ngoc Xuan Trang



CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Phường Phương Liệt - Hà Nội

Website: <http://www.mediplantex.com>

No. 02/2026/BC-MED

Hanoi, June 29, 2026

REPORT OF THE BOARD OF MANAGEMENT ON THE 2025 BUSINESS AND PRODUCTION RESULTS AND THE IMPLEMENTATION PLAN FOR 2026

To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company

I. BUSINESS PERFORMANCE RESULTS IN 2025:

1. Advantages Factors during the Year:

- Mediplantex is a reputable brand with high-quality products that are trusted by its partners.
- The Board of Directors provides close and consistent guidance, always setting strategic directions and creating favorable conditions for the Board of Management to operate in close alignment with approved policies and orientations. The leadership team demonstrates vision and innovation.
- The quality management system is maintained and operated effectively, with strict control from input materials to final product release, ensuring stable product quality and full compliance with legal regulations.
- The workforce is experienced and continuously improves the management system and production organization. This is a key factor enabling the Company to maintain stable operations and enhance operational efficiency.
- The strengthening of regulatory enforcement by state authorities in handling substandard products, counterfeit goods, and goods of unclear origin has contributed to a more transparent competitive environment, creating favorable conditions for compliant enterprises such as Mediplantex.
- The Company continues to receive consensus, support, and partnership from its shareholders in the implementation of its production and business activities.

2. Challenges in Implementing the Business and Production Plan:

- The domestic and international economic environment remained volatile, affecting production costs and the Company's operations. The prices of certain raw materials, particularly imported inputs, showed an increasing trend and longer supply lead times, creating pressure on production planning and cost control.



- Regulatory requirements in the pharmaceutical sector have become increasingly stringent. Requirements for product registration dossiers, maintenance of marketing authorizations, and product disclosure have become more demanding, while post-licensing inspections and regulatory audits have been strengthened. As a result, dossier evaluation and approval timelines have become longer than before.
- The workforce structure at manufacturing plants and intermediary departments remains relatively cumbersome and has not yet been streamlined. A large number of employees engaged in production has led to high personnel management costs. In the context of economic challenges, optimizing labor resources remains a significant challenge in balancing operational efficiency and cost control.

3. Business Results for 2025:

(Unit: Million VND)

No.	Indicators	Actual 2024	Plan 2025	Actual 2025	2025 Actual / 2024 Actual	% of 2025 Plan
A	Total Sales Revenue	443,136	299,907	366,830	83%	122%
1	Revenue from Sales	439,711	296,207	362,886	83%	123%
1.1	Sales Revenue – Business Division	364,909	284,925	300,696	82%	106%
1.2	Export Sales Revenue	72,601	11,282	60,410	83%	535%
1.3	Raw Material Sales Revenue	562		1,780	317%	
1.4	Sales Revenue – HCMC Branch	1,638		0		
2	Service Revenue	3,425	3,700	3,944	115%	107%
2.1	Entrusted Services	687	700	570	83%	81%
2.2	Leasing Services	2,738	3,000	3,374	123%	112%
B	Cost of Goods Sold	350,574	223,095	281,043	80%	126%
C	Gross Profit	92,561	76,812	85,787	93%	112%
4	Financial Income	2,194		1,371	62%	
5	Financial Expenses	5,882	3,850	3,675	62%	95%
6	Selling Expenses	7,956	5,009	4,734	60%	95%
7	Administrative Expenses	62,411	55,049	58,627	94%	106%
D	Operating Profit	18,506	12,904	20,122	109%	156%
8	Other Income	1,194		622	52%	
9	Other Expenses	282		85	30%	
E	Profit Before Tax	19,418	12,904	20,659	106%	160%

- Although revenue decreased by 17% compared to 2024, profit before tax reached VND 20.7 billion, increasing by 6% year-on-year, thanks to the Company's synchronized implementation of solutions to improve operational efficiency, focusing on cost of goods sold control, reduction of financial and selling expenses, optimization of the management structure, and enhancement of revenue structure efficiency. These efforts helped offset the impact of declining revenue and maintain overall business performance.
- In addition, in 2025, state regulatory authorities strengthened inspections and examinations in the pharmaceutical manufacturing and trading sector, particularly for functional foods, including periodic GMP re-evaluation inspections. The Company received a total of five (05) inspection and audit teams from competent authorities. As a result, the production of certain product lines was delayed or could not be supplied to customers on schedule. Furthermore, some customers also reduced order volumes compared to the initial annual plan. By the end of 2025, production and sales activities with key customers had stabilized again, resulting in improved business performance compared to the approved plan.
- Although administrative expenses decreased compared to 2024 actual levels, the Company did not fully achieve its planned cost reduction targets for administrative expenses.

4. Performance Indicators Achieved:

4.1. Human Resource Management

- In 2025, the Company streamlined approximately 10% of indirect and administrative workforce, while simultaneously recruiting additional specialized personnel for Research & Development (R&D), Quality Control (QC), and production departments to meet product development requirements and maintain GMP compliance.
- Following the organizational restructuring, average labor productivity increased by 5–7% compared to the same period in 2024. The current workforce is more specialized, with younger staff being trained and exposed to new technologies.
- In addition, the Company has continuously focused on employee training, sending staff to various training programs organized by the Ministry of Health to update regulations on drug registration, pharmaceuticals, and quality management. In the coming period, the Company plans to implement leadership and management skills training programs for key personnel.

4.2. Financial Management

- Effectively managed receivables, monitored overdue debts, and actively worked with customers to accelerate debt collection.
- Maintained a safe liquidity position, ensuring balanced cash flows to support regular production and business activities as well as investment needs.
- Strengthened the roles and responsibilities of internal control functions across the Company.

- Enhanced foreign exchange risk management to stabilize import input costs and improve financial planning flexibility.
- Reviewed inventory structure and optimized inventory turnover to reduce risks related to quality deterioration of raw materials and finished goods.

4.3. Product Quality Management

- Continued to effectively maintain the quality management system in compliance with GMP-WHO standards, ISO standards, and relevant legal regulations.
- Invested in an additional HPLC system to enhance testing capacity and product research and development, serving quality control of raw materials, semi-finished products, and finished products, while meeting requirements for research, validation, and quality management under current GMP regulations.

4.4. Production and Product Research & Development

- Total production output of the two factories in 2025 reached approximately 527 million product units, exceeding the 2025 production plan by 2.6%.
- Production activities were carried out stably, ensuring compliance with GMP requirements, occupational safety, and quality control throughout the entire production process. No occupational accidents or serious incidents affecting the Company's operations occurred during the year.
- The factories strengthened production process control, optimized equipment operations, reviewed raw material consumption norms, and reduced production costs to improve operational efficiency amid competitive pressure and fluctuating input costs.
- R&D activities remained stable. The Company promptly appointed the former Deputy Head of the R&D Department as Head of R&D following the resignation of the previous Head. The Board of Management focused on directing improvements in formulations, production processes, and quality standards for various existing products to enhance quality, optimize costs, and ensure compliance with approved registration dossiers.
- Many products were improved in line with approved drug registration dossiers, meeting updated regulatory requirements and contributing to risk reduction during production and commercialization, while strengthening GMP compliance.

Stt	Indicator	Unit	2024	2025
1	Newly granted marketing authorizations (registration numbers)	Products	23	24
2	Renewed marketing authorizations	Products	157	12
3	Approved variations, amendments, and updates	Products	192 (including 14	203 (including 32 active pharmaceutical

Stt	Indicator	Unit	2024	2025
			manufacturing site supplement dossiers)	ingredient/manufacturing site supplement dossiers)
4	Newly implemented products	Products	18	11
5	Products with formulation and manufacturing process improvements implemented	Products	5	14

II. BUSINESS OPERATION ORIENTATION FOR 2026

1. Challenges and Difficulties in Implementing the 2026 Plan

The year 2026 is forecast to remain challenging for the global economy across multiple sectors:

- Global geopolitical instability: Ongoing tensions in certain regions, including the Middle East, are expected to persist, disrupting global supply chains and causing difficulties in importing raw materials, excipients, and packaging materials for production.
- New tariff policies and trade protection measures: Policy adjustments in several countries may increase logistics costs, raise import expenses, and heighten risks in export expansion, thereby affecting the Company's international trade plans.
- Foreign exchange volatility: Fluctuations in foreign currencies, particularly USD and CNY, are expected to impact imported input costs—which account for a significant proportion of production costs—putting pressure on profit margins, pricing policies, competitiveness, and overall business performance. In some cases, this may even disrupt the supply of raw materials.
- Intensifying domestic pharmaceutical competition: The domestic pharmaceutical market is expected to remain highly competitive, especially in the generic drug and health supplement segments. Large-scale enterprises continue to invest heavily in distribution systems, product development, and market expansion, creating significant pressure on companies with similar scale and operating models such as Mediplantex.
- Regulatory and licensing challenges: Difficulties in drug registration, renewal, and variation approvals remain a major challenge for the pharmaceutical industry. Longer review and approval timelines may delay the launch of new products, limit portfolio expansion, and negatively affect revenue growth and customer acquisition.
- Increasing compliance requirements: Stricter standards in GMP, GSP, GDP, quality management, traceability, and drug registration dossiers are significantly increasing compliance costs for enterprises.

2. 2026 Production and Business Plan with Key Performance Indicators:

(Unit: Million dong)

No.	INDICATOR	UNIT	VALUE
I	Total Revenue	Million VND	412,071
II	Cost of Goods Sold	Million VND	321,273
III	Total Gross Profit	Million VND	90,797
IV	Total Selling Expenses	Million VND	4,949
	Financial Expenses	Million VND	5,120
V	Administrative Expenses	Million VND	62,822
VI	Profit Before Tax	Million VND	15,005

The 2026 business plan is developed on a prudent basis, fully reflecting the existing risk factors in the pharmaceutical industry, including:

- Difficulties in the drug registration approval process;
- Exchange rate fluctuations and rising imported raw material costs;
- International tariff and trade policy changes;
- Increasing competitive pressure in the market;
- Investment costs related to digital transformation, ERP implementation, and corporate restructuring.

The Board of Management determines that the approved plan represents the minimum target to be achieved, and at the same time commits to striving to exceed the plan in order to maximize benefits for shareholders

3. Operational Orientation:

- Continue implementing the restructuring plan toward a lean and efficient organization, and deploy an ERP enterprise resource planning system to modernize the management model, optimize operational efficiency, and standardize production and business processes through comprehensive digitalization.
- Strengthen market development by expanding customer networks and enhancing cooperation with both domestic and international partners. Maintain stable production volumes with key strategic customers and develop export markets through international trade promotion activities to expand revenue.
- Develop new products and improve formulations and production processes of existing products to enhance competitiveness and meet increasingly sophisticated market demand.
- Continue reviewing internal regulations, procedures, and professional guidelines to ensure full compliance with GMP, GSP, GDP, and corporate governance requirements. Standardize products to ensure consistent quality and minimize the risk of quality-related violations or product recalls.

- Improve production management efficiency to reduce waste, optimize material usage, and ensure rational labor allocation, thereby lowering production costs and increasing product competitiveness.
- Develop optimized inventory and procurement plans to achieve favorable supplier terms, reduce input costs for raw materials and packaging, and improve purchasing efficiency.
- Effectively implement financial management solutions in cash flow, inventory, and debt management, and restructure borrowing to ensure sufficient capital for production, business operations, and investment activities in 2026.

Overall Assessment:

- Although 2025 was a challenging year for the pharmaceutical industry and the Company's business operations, the Company maintained stable operations, ensured full compliance with applicable laws and regulations, and exceeded the profit targets assigned by the General Meeting of Shareholders.
- These results reflect the strong efforts of the entire workforce, the close direction and supervision of the Board of Directors and the Board of Supervisors, as well as the continuous support and companionship of shareholders throughout the Company's operations.
- In 2026, the Board of Management will continue to build on the achieved results, proactively respond to market challenges and uncertainties, focus on improving operational efficiency, and ensure sustainable growth while maximizing value for shareholders.

The above is the report of the Board of Management on the business performance in 2025 and the orientation for the implementation of the 2026 business plan.

Respectfully proposes to the General Meeting of Shareholders for consideration and approval.

Recipients:

- BOD
- BOM
- Shareholders
- SSC
- Archived: Secretary



GENERAL DIRECTOR
Mai Nhat Thanh

CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Phường Phương Liệt - Hà Nội

Website: <http://www.mediplantex.com>



No: 03/2026/BC-MED

Hanoi, June 29, 2025

REPORT OF THE BOARD OF SUPERVISORS ON THE 2025 ACTIVITIES, SUPERVISORY WORK AND THE PROPOSED PLAN FOR 2026

To: The General Meeting of Shareholders

- Pursuant to the Law on Enterprises and the Charter of MediPlantex National Pharmaceutical Joint Stock Company stipulating the functions and authority of the Board of Supervisors;

- Pursuant to the Resolution of the 2024 General Meeting of Shareholders and the Resolutions of the Board of Directors in 2024;

- Pursuant to the business performance results and the audited 2025 financial statements;

The Board of Supervisors (BOS) of MediPlantex National Pharmaceutical Joint Stock Company respectfully submits to the Annual General Meeting of Shareholders (GMS) the report on its activities in 2025 and the proposed plan for 2026, with the following key contents:

I. Organization and Activities of the Board of Supervisors:

1. Personnel of the Board of Supervisors:

The Board of Supervisors consists of 3 members, including:

- Mr. Ho Ngoc Tuan : Head of the Board of Supervisors
- Ms. Ha Thi Bich Hanh : Member of the Board of Supervisors
- Ms. Do Ngoc Thuy : Member of the Board of Supervisors

2. Activities of the Board of Supervisors:

During the year, the Board of Supervisors fully performed its duties and responsibilities as assigned by the General Meeting of Shareholders, specifically overseeing, inspecting, and supervising the Company's governance, management, and business operations. The Board operated with a strong sense of responsibility, clearly delegated tasks to each member, and appointed representatives to attend meetings of the Board of Directors (BOD) and the Board of Management (BOM).

The Board of Supervisors maintained close and regular working relations with the BOD and the General Director in business operations, monitoring the Company's



activities to ensure compliance with applicable laws, exchanged information with the BOD and General Director regarding the implementation of business plans and resolutions approved by the General Meeting of Shareholders.

Based on its functions and duties as stipulated by the Law on Enterprises, the Company's Charter, and the Regulations on Organization and Operation of the Board of Supervisors, the Board carried out the following activities during the year:

- Attended the Company's Annual General Meeting of Shareholders.
- Participated in regular and extraordinary meetings of the Board of Directors.
- Monitored financial and accounting activities, including review of the semi-annual and annual financial statements of the Company.
- Supervised the activities of the BOD and the Board of Management in accordance with the law and resolutions of the General Meeting of Shareholders.
- Oversaw the Company's information disclosure in compliance with legal regulations.
- Proposed the selection of an independent auditing firm to audit the Company's annual and semi-annual financial statements; assessed the financial statements before and after the audit.
- Provided input on the development of operating regulations for the Company by the BOD and the Board of Management.
- Cooperated with relevant departments to inspect and assess business operations.
- Held regular and extraordinary meetings of the Board of Supervisors to review, discuss, and evaluate the Company's performance, in which:
 - + A meeting to review the Supervisory Board's performance in 2025 and approve its operational plan for 2026.
 - + A meeting to consider and recommend the appointment of an independent audit firm to audit the Company's 2026 financial statements for submission to the Annual General Meeting of Shareholders for approval.
 - + A meeting to review the independent auditor's report for the financial year ended 31 December 2025.
- Performed other duties in accordance with the functions and responsibilities of the Board of Supervisors.

3. Remuneration, Salaries and Other Benefits of the Members of the Supervisory Board

During 2025, the remuneration, salaries and other benefits paid to the members of the Supervisory Board are presented in the audited Financial Statements for the year ended 31 December 2025.

II. Evaluation by Task Group:

1. Evaluation by the BOS on the Activities of the BOD:

- Governance activities were carried out in accordance with the law, the Company's Charter, and the resolutions of the General Meeting of Shareholders.

- The BOD ensured transparency and openness in management, with a strategic focus on business development and efficiency.

- The BOD held regular meetings with clear agendas, documented minutes, and issued resolutions instructing the General Director to implement decisions. However, in the past period, the BOD was unable to organize meetings as regularly planned due to the health condition of the Chairman. The BOS recommends that the BOD resume regular meetings as prescribed.

- During the year, the BOD amended, supplemented, and issued several regulations, documents, resolutions, and decisions, providing a structured, focused, and unified foundation for corporate governance.

2. Evaluation by the BOS on the General Director's Implementation of Resolutions of the GMS and the BOD:

- The General Director implemented various measures to strengthen financial management by controlling expenses, monitoring customer receivables, and managing operational activities in line with the objectives set by the General Meeting of Shareholders and the BOD.

- Took the initiative in executing the business plan, fully fulfilled obligations to the State and shareholders, and paid attention to employee welfare.

- Organized the year-end review conference to comprehensively evaluate business operations, identify limitations and shortcomings, and propose appropriate solutions and corrective actions.

- Focused on addressing internal weaknesses of the Company to improve operational efficiency and reduce costs.

- Regarding investment and co-investment projects that are behind schedule, the Board of Supervisors submitted recommendations to the BOD and the Board of

Management, requesting a thorough review to ensure legal compliance and investment efficiency.

- For several resolutions issued by the BOD that have not yet been implemented, the Board of Supervisors recommends that the BOM promptly report back to the BOD on the reasons for the delay and the implementation progress.

III. Review and Evaluation of Financial Statements:

1. Preparation and Audit of Financial Statements:

- The Company's financial statements were prepared in accordance with current Vietnamese Accounting Standards. The annual and semi-annual financial statements were audited by AASC Auditing Firm Company Limited.

- The Board of Supervisors reviewed the financial statements and concurred with the reported business results. According to the audit opinion provided by AASC, the Company's financial statements were presented fairly, accurately, completely, and clearly, and were in compliance with applicable accounting standards.

However, the auditing firm issued a qualified opinion on the Company's 2025 audited financial statements, not an unqualified opinion, due to a limitation in the audit scope related to two business cooperation contracts: Contract No. 68/HDHTKD dated June 1, 2017 (cooperation in developing the project at the land lot located at 190 Dinh Thon Street, My Dinh 1 Ward, Nam Tu Liem District) and Contract No. 35/2009/HĐHT dated December 25, 2009 (cooperation in developing the project at the land lot located at 118 Nguyen Van Troi Street, Phuong Liet Ward, Thanh Xuan District). As the Company is currently working with its partners and relevant authorities on the implementation of these contracts, the information has not yet been provided to the auditors.

Regarding this matter, the Board of Supervisors has required that the Company engage a consulting firm to promptly resolve the issue and protect the Company's rights and interests in accordance with regulations. In addition, the Board of Supervisors has submitted its recommendations on this matter to the BOD and BOM, and requested that the BOD and BOM take appropriate action and implement necessary solutions.

2. Business Performance Results:

The Company closely followed the business targets set by the GMS and focused on implementing solutions to enhance production capacity, improve product quality, reduce costs, and increase operational efficiency.

IV. Recommendations for the Board of Directors and the General Director to continue addressing in the coming period:

- The BOD should consider developing a long-term business strategy to enhance proactiveness in operations.

- Improve and strengthen training and recruitment of qualified and experienced staff, as well as highly skilled technical workers, to support future business and production activities.

- Continue implementing more effective measures to recover due receivables and bad debts.

- Accelerate the implementation of the Pharmaceutical Science and Technology Center and the EU-GMP-standard Pharmaceutical Manufacturing Plant Project to bring it into efficient operation as soon as possible.

V. Report on Transactions between the Company and Members of the Board of Directors, the General Director, other executive officers, and their related persons; and transactions between the Company and companies in which members of the Board of Directors, the General Director, or other executive officers are founders or managers within the last three (03) years prior to the transaction date

In 2025, all transactions between the Company and related parties were submitted to and approved by the Board of Directors in accordance with proper procedures and were fully compliant with disclosure obligations. Details of related-party transactions are presented in the audited Financial Statements for 2025 and the Company's Corporate Governance Report. The Board of Supervisors confirms that the transaction procedures complied with regulations, with no violations detected. The transactions were conducted in a transparent manner, ensuring effective control of conflicts of interest and safeguarding the interests of the Company and its shareholders.

VI. Work Plan of the Board of Supervisors for 2026:

- Perform inspection and supervision duties over the governance and management activities of the Board of Directors and the Board of Management in accordance with the Company's Charter and the Law on Enterprises;

- Monitor the implementation of resolutions of the General Meeting of Shareholders and resolutions of the Board of Directors in the course of business operations, based on legal regulations and the Company's Charter;

- Review the appropriateness of internal documents and management regulations and their practical application to ensure alignment with the resolutions of the General Meeting of Shareholders. Propose amendments or supplements to internal regulations if deemed necessary;

- Examine accounting records, vouchers, and other Company documents when necessary or upon request of the General Meeting of Shareholders;
- Propose the selection of an independent auditing firm to audit the Company's semi-annual and annual financial statements;
- Review and evaluate financial statements and the Company's business performance on a quarterly, semi-annual, and annual basis;
- Maintain close coordination between the Board of Supervisors, the Board of Directors, the Board of Management, and other relevant units within the Company;
- Participate in major Company activities to stay informed about business operations;
- Attend BOD meetings and quarterly briefings to stay up to date on the Company's situation.

VII. General Assessment of the Activities of the Board of Supervisors:

- The Board of Supervisors performed its functions and duties in accordance with the Company's Charter and the relevant provisions of the Law on Enterprises relating to the Board of Supervisors.

- The Board of Supervisors fulfilled the responsibilities entrusted to it by shareholders, particularly in overseeing business operations and the effective use of capital.

- The performance of the Board of Supervisors during the term was the result of the efforts of each member, as well as the trust, support, and facilitation provided by the Board of Directors, the General Director, departments, and all employees of the Company.

On behalf of the Board of Supervisors, I would like to sincerely thank the General Meeting of Shareholders, the Board of Directors, and the General Director for their trust, support, and cooperation throughout the past year, which enabled the Board of Supervisors to fulfill its duties effectively.

Respectfully!

Recipient:

- Shareholders;
- BOD; BOM;
- BOS;
- Archived: BOS; Secretary; Office.

**ON BEHALF OF THE BOARD OF SUPERVISORS
HEAD OF THE BOARD**



Ho Ngoc Tuan

No.: 01/2026/TTr-ĐHĐCĐ

THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Hanoi, June 29, 2026

PROPOSAL

Re: Approval of the 2025 Audited Financial Statements

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 adopted by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and effective from January 1, 2021, as amended by Law No. 03/2022/QH15 adopted by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;
- Pursuant to the Charter on organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;
- Pursuant to the 2025 financial statements of Mediplantex National Pharmaceutical Joint Stock Company, audited by AASC Auditing Firm Company Limited.

The Board of Directors respectfully submits to the General Meeting of Shareholders of the Company for consideration and approval the following matter:

In accordance with the Resolution of the 2025 Annual General Meeting of Shareholders regarding the selection of an independent auditing firm for the 2025 financial statements, the Company appointed AASC Auditing Firm Company Limited to conduct the independent audit of the 2024 financial statements.

The Company's 2025 financial statements were independently audited by AASC Auditing Firm Company Limited, with the audit report signed on March 06, 2026.

Respectfully submits to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- Company Shareholders;
- BOD; BOM;
- BOS;
- Archived: Company Secretary.

OB. THE BOARD OF DIRECTORS

CHAIRMAN 



Nguyen Ngoc Xuan Trang



MEDIPLANTEX

CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Phường Phương Liệt - Hà Nội

Website: <http://www.mediplantex.com>



No.: 02/2026/TTr-DHĐCĐ

THE SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June 29, 2026

PROPOSAL

Re: Selection of the Independent Auditing Firm for the 2026 Financial Statements

To: The General Meeting of Shareholders

of Mediplantex National Pharmaceutical Joint Stock Company

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;
- Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company.

The Board of Supervisors of Mediplantex National Pharmaceutical Joint Stock Company respectfully submits to the General Meeting of Shareholders for consideration and approval the following matter:

In order to ensure proactivity in selecting an appropriate auditing firm that meets the Company's requirements regarding the timing and quality of auditing services for the financial statements of the fiscal year 2026, the Board of Supervisors respectfully proposes that the General Meeting of Shareholders consider and approve the following contents:

1. Approval of criteria for selecting the independent auditing firm for the 2026 Financial statements:
 - The auditing firm must be an independent audit enterprise included in the list of entities eligible to provide audit services as announced by the Ministry of Finance at the time of selection. It must fully meet all professional standards and conditions, possess a team of qualified auditors, and be approved by the State Securities Commission to audit public interest entities operating in the securities sector in 2026.
 - The firm must have a strong reputation and extensive experience in the field.
 - The firm must not have any conflicts of interest in connection with auditing the Corporation's financial statements.
 - The proposed audit fee must be competitive and appropriate to the content, scope, and timeline of the audit engagement.



2. Approval of the following list of auditing firms proposed to conduct the audit of the financial statements for the fiscal year 2026 and the review of the quarterly and semi-annual financial statements (if required by State regulatory authorities) for Mediplantex National Pharmaceutical Joint Stock Company, including:
 - 1.1. KPMG Company Limited;
 - 1.2. AASC Auditing Firm Company Limited;
 - 1.3. PWC (Vietnam) Company Limited;
 - 1.4. Viet Nam Auditing & Evaluation Company Limited;
 - 1.5. An Viet Auditing Company Limited.
 - 1.6. Other audit firms included in the list of audit companies approved by the State Securities Commission to audit public interest entities in the securities sector for the year 2026.
3. Estimated auditing fee: From VND 200,000,000 to VND 500,000,000.
4. The Board of Supervisors respectfully submits to the General Meeting of Shareholders a proposal to authorize the Board of Directors to select one of the aforementioned auditing firms to conduct the audit and review of the 2026 financial statements. In case the selected auditing firm is unable to continue the audit and review, or if the Board of Directors deems that the selected firm cannot ensure timely issuance of the reports, the Board of Supervisors seeks the General Meeting's authorization for the Board of Directors to change the auditing firm, provided that the replacement meets the required criteria and is selected from the list previously approved by the General Meeting of Shareholders. Any change of auditing firm will be disclosed as an extraordinary information disclosure in accordance with the prevailing laws and regulations on information disclosure in the securities market.
5. The Board of Directors authorizes the General Director / Legal Representative to sign the audit contract with the selected auditing firm.

Respectfully submits to the General Meeting of Shareholders for consideration and approval.

Recipients:

- *Company Shareholders;*
- *BOD; BOM;*
- *BOS;*
- *Archived: Company Secretary.*

**OB. THE BOARD OF SUPERVISORS
HEAD OF THE BOARD**



Ho Ngoc Tuan





CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Phường Phương Liệt - Hà Nội

Website: <http://www.mediplantex.com>

No.: 03/2026/TTr-ĐHĐCĐ

THE SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June 29, 2026

PROPOSAL

Re: Approval of the profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

Pursuant to:

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, effective as of January 1, 2021, and amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;
- Pursuant to the Charter on the organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;
- Pursuant to the 2025 financial statements of Mediplantex National Pharmaceutical Joint Stock Company audited by AASC Auditing Firm Company Limited;
- The 2025 business and production results and the implementation plan for 2026.

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the following matter:

I. PROFIT DISTRIBUTION PLAN FOR 2025:

Indicators	Percentage (%)	Value (Unit: VND)
1. Profit before tax in 2025		20,659,417,001
2. Corporate income tax payable in 2025		4,825,980,517
3. Profit after tax in 2025		15,833,436,484
4. Profit distribution in 2025		15,833,436,484

Indicators	Percentage (%)	Value (Unit: VND)
4.1. Bonus allocation to the Board of Management		158,334,365
4.2. Bonus allocation to the Board of Directors and the Board of Supervisors		158,334,365
4.3. Allocation to the Development Investment Fund	0%	2,000,000,000
4.4. Remaining profit for dividend distribution		13,516,767,754
5. Retained earnings from previous years		365,519,888
6. Total profit for dividend distribution up to the end of 2025		13,882,287,642
7. Proposed dividend distribution	0%	0
8. Retained earnings for 2026		13,882,287,642

Reason for not paying dividends: To retain funds for working capital requirements and for payment of land clearance and site clearance costs relating to the GMP-EU Manufacturing Plant Project at Hoa Lac High-Tech Park.

II. PLAN FOR 2026

Based on the 2026 business and production plan of Mediplantex National Pharmaceutical Joint Stock Company, the Board of Directors proposes the allocation of bonuses and the dividend payout rate for 2026 as follows:

Projected for 2026	Percentage %	Amount VND
I. Profit Before Tax 2025		15,005,000,000
II. Profit After Tax 2025		12,004,000,000
1. Allocation for bonus to the Board of Management	1%	120,040,000
2. Allocation for bonus to the Board of Directors and the Board of Supervisors	1%	120,040,000
3. Allocation to the Development Investment Fund	0	
4. Remaining profit for dividend distribution	10% of charter capital	13,882,287,642
5. Retained earnings for 2027		12,410,000,000

- The allocation of bonuses to the Board of Management and to the Board of Directors and the Board of Supervisors at the above-mentioned rates shall only be implemented if the



profit after tax in 2026 reaches 90% to 100% of the 2026 approved plan.

- In the event that the 2026 performance exceeds the plan approved by the General Meeting of Shareholders:
 - + Additional bonus for the Board of Management at the rate of 05% of the excess amount over the plan.
 - + Additional bonus for the Board of Directors and the Board of Supervisors at the rate of 05% of the excess amount over the plan.

Respectfully submits to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- Shareholders of Mediplantex National Pharmaceutical Joint Stock Company;
- BOD, BOS, BOM, Company Secretary
- Archived: Office, BOD.

**OB. THE BOARD OF DIRECTORS
CHAIRMAN**



Nguyen Ngoc Xuan Trang



No.: 04/2026/TTr-ĐHĐCĐ

THE SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June 29, 2026

PROPOSAL

Re: Approval of remuneration for the Board of Directors and the Board of Supervisors for 2025 and the plan for 2026

To: The General Meeting of Shareholders

of Mediplantex National Pharmaceutical Joint Stock Company

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, effective as of January 1, 2021, and amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;
- Pursuant to the Charter on the organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;
- Pursuant to the 2025 financial statements of Mediplantex National Pharmaceutical Joint Stock Company audited by AASC Auditing Firm Company Limited;
- The 2025 business and production results and the implementation plan for 2025.

The Board of Directors respectfully submits to the General Meeting of Shareholders the following matter for consideration and approval:

In regard to the activities of the Board of Directors and the Board of Supervisors in carrying out their assigned duties in 2025, the Company hereby reports the remuneration of the Board of Directors and the Board of Supervisors for the year 2025:

1. Remuneration of the Board of Directors and the Board of Supervisors in 2025:

No.	Position	Number	Remuneration/year
Remuneration of the Board of Directors			646.000.000
1	Chairman of the BOD	1	110,000,000
2	Independent member of the BOD	1	84,000,000
3	Member of the BOD (including Executive and Non-Executive Members)	3	252,000,000
Total Remuneration of the Board of Directors in 2025			446,000,000

No.	Position	Number	Remuneration/year
	Additional Remuneration to be Paid for 2025		200,000,000
Remuneration of the Board of Supervisors, Company Secretary			204,000,000
1	Head of the BOS	1	54,000,000
2	Member of the BOS	2	84,000,000
3	Company Secretary	1	54,000,000
Total Remuneration of the Board of Supervisors in 2025			192,000,000
	Additional Remuneration to be Paid for 2025		12,000,000

Other benefits of members of the Board of Directors and the Board of Supervisors shall be provided in accordance with applicable laws, the Company's Charter and internal regulations, and have been fully disclosed in the audited Financial Statements for the fiscal year ended 2025.

2. Plan Remuneration for 2026:

To ensure the effective operation of the Board of Directors and the Board of Supervisors in carrying out their assigned duties in 2026, and based on the business plan of Mediplantex National Pharmaceutical Joint Stock Company for 2026, as well as relevant regulations of the State, the Company's Charter, and internal regulations, the Board of Directors respectfully submits for approval the plan total remuneration for 2026:

No.	Position	Number	Remuneration/year
Remuneration of the Board of Directors			648,000,000
1	Chairman of the BOD	1	360,000,000
	(In the case of a Non-Executive Chairman of the Board of Directors)	1	180,000,000
2	Independent member of the BOD	1	72,000,000
3	Member of the BOD (including Executive and Non-Executive Members)	3	216,000,000
Remuneration of the Board of Supervisors, Company Secretary			156,000,000
1	Head of the BOS	1	48,000,000
2	Member of the BOS	2	72,000,000
3	Company Secretary	1	36,000,000

Respectfully submits to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- Shareholders;
- BOD, BOS, BOM, Company Secretary
- Archived: Office, BOD.

**OB. THE BOARD OF DIRECTORS
CHAIRMAN**



Nguyen Ngoc Xuan Trang



No.: 06/2026/TTr-ĐHĐCĐ

THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Hanoi, June 29, 2026

PROPOSAL

Re: Approval of the Dismissal of Ms. Nguyen Thi Thuy as a Member of the Board of Directors and the Election of an Additional Member of the Board of Directors for the 2024 – 2029 Term

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;

- Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company;

- Pursuant to the Regulation on the Operation of the Board of Directors of the Company;

- Based on the letter of resignation submitted by the member of the Board of Directors to the Board of Directors;

The Board of Directors respectfully proposes to the General Meeting of Shareholders of the Company for consideration and approval of the following matters:

1. Based on the resignation letter submitted by a member of the Board of Directors, the Board respectfully proposes that the General Meeting of Shareholders approve the dismissal of:

Ms. Nguyen Thi Thuy - Member of the Board of Directors for the 2024–2029 term

Upon the approval of Ms. Nguyen Thi Thuy's resignation, the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company for the 2024–2029 term will consist of only 04 members, thereby failing to meet the structural requirements of the Board of Directors as prescribed by the Company's Charter. Accordingly, the Board of Directors deems it necessary to propose the election of an additional member to the Board of Directors for the 2024–2029 term.

2. The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the election of an additional member of the Board of Directors for the 2024 – 2029 term to replace Ms. Nguyen Thi Thuy, with the following contents:



- Number of additional members to be elected to the BOD: 01 member
- Criteria for selecting a member of the BOD: In accordance with Clause 2, Article 155 of the Law on Enterprises and Article 7 of the Regulations on the Operation of the BOD.
- Number of candidates: Unlimited.

Respectfully proposes to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- *Company Shareholders;*
- *BOD; BOS;*
- *Archived: Company Secretary.*

OB. THE BOARD OF DIRECTORS



Nguyen Ngoc Xuan Trang



No.: 07/2026/TTr-ĐHĐCĐ

THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Hanoi, June 29, 2026

PROPOSAL

Re: Approval of the Dismissal of Ms. Tran Nguyen Hoang Phuc as a Member of the Board of Directors and the Election of an Additional Member of the Board of Directors for the 2024 – 2029 Term

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;

- Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company;

- Pursuant to the Regulation on the Operation of the Board of Directors of the Company;

- Pursuant to the Resolution of the Board of Directors No. 08/2026/NQ-HĐQT dated May 25, 2026 regarding the supplementation of the agenda of the 2026 Annual General Meeting of Shareholders.

The Board of Directors respectfully proposes to the General Meeting of Shareholders of the Company for consideration and approval of the following matters:

1. The Board of Directors respectfully submits to the General Meeting of Shareholders for approval the dismissal of:

Ms. Tran Nguyen Hoang Phuc - Member of the Board of Directors for the 2024–2029 term

To ensure that the Company's governance and management activities are carried out continuously, stably and effectively, in compliance with applicable laws and the Company's Charter, the Board of Directors considers it necessary to elect an additional member of the Board of Directors for the 2024 – 2029 term.

2. The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the election of an additional member of the Board of Directors for the 2024 – 2029 term to replace Ms. Tran Nguyen Hoang Phuc, with the following contents:

- Number of additional members to be elected to the BOD: 01 member



- Criteria for selecting a member of the BOD: In accordance with Clause 2, Article 155 of the Law on Enterprises and Article 7 of the Regulations on the Operation of the BOD.
- Number of candidates: Unlimited.

Respectfully proposes to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- *Company Shareholders;*
- *BOD; BOS;*
- *Archived: Company Secretary.*

OB. THE BOARD OF DIRECTORS

CHAIRMAN 


Nguyen Ngoc Xuan Trang





CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Phường Phương Liệt - Hà Nội

Website: <http://www.mediplantex.com>

No.: 05/2026/TTr-ĐHĐCĐ

THE SOCIALIST REPUBLIC OF VIETNAM

Independence - Freedom - Happiness

Hanoi, June 29, 2026

REPORT

Re.: Approval of the Amendments and Supplements to the Charter on Organization and Operation of the Company

To: The General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, effective as of January 1, 2021, and amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;
- Pursuant to the Charter on the organization and operation of Mediplantex National Pharmaceutical Joint Stock Company.

The Board of Directors respectfully submits the following to the General Meeting of Shareholders for consideration and approval:

Based on a review of the Company's Charter on Organization and Operation (the "Charter"), the Board of Directors has determined that certain provisions of the Charter should be amended and supplemented to ensure compliance with applicable laws and regulations and to meet practical requirements in the Company's governance and management. (Details of the proposed amendments and supplements are set out in the Appendix attached to this Proposal.)

The full draft of the amended Charter has been published in detail on the Company's website at: <https://www.mediplantex.com/>.

The General Meeting of Shareholders is respectfully requested to authorize the Board of Directors and the Company's Legal Representative to make amendments and supplements to, and to execute and promulgate, the Charter and related documents based on the amendments and supplements approved by the General Meeting of Shareholders.



Furthermore, with respect to any administrative procedures arising from the amendments and supplements to the Charter, the General Meeting of Shareholders is respectfully requested to consider, approve, and authorize the Board of Directors and the Company's Legal Representative to carry out such procedures in accordance with the approved contents.

The amended and supplemented Charter on Organization and Operation shall take effect from the date of its approval by the Company's 2026 Annual General Meeting of Shareholders. Any administrative procedures arising therefrom shall be carried out within the time limits prescribed by applicable laws and regulations.

Respectfully submitted to the General Meeting of Shareholders for consideration and approval./.

Recipient:

- Company shareholders;
- Board of Directors, Supervisory Board, Company Secretary;
- Lưu VT, Board of Directors.

OB. THE BOARD OF DIRECTORS

CHAIRMAN



Nguyen Ngoc Xuan Trang



No.: 01/2026/NQ-DHDCD/MED

Hanoi, June 29, 2026

RESOLUTION
2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

Pursuant to:

- Pursuant to the Law on Enterprises No. 59/2020/QH14 adopted by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and effective from January 1, 2021, as amended by Law No. 03/2022/QH15 adopted by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;
- Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26, 2019, passed by the National Assembly of the Socialist Republic of Vietnam, as amended by Law No. 56/2024/QH15 passed by the National Assembly of the Socialist Republic of Vietnam on November 29, 2024, and its guiding documents;
- Pursuant to the Charter on organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;
- Pursuant to the Minutes of the 2026 Annual General Meeting of Shareholders No. 01/2026/BB-DHDCD/MED dated June 29, 2026;
- Pursuant to the Vote Counting Minutes of the 2026 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company dated June 29, 2026.

The 2026 Annual General Meeting of Shareholders (“AGM” or “GMS”) of Mediplantex National Pharmaceutical Joint Stock Company shall be conducted in the form of an online meeting with electronic voting. The meeting venue for the Chairperson, and the Organizing Committee (the principal venue from which the Meeting is conducted) shall be located at: No. 358 Giai Phong Road, Phuong Liet Ward, Hanoi, Vietnam.

RESOLUTION

Article 1. Approval of the following reports:

- Report of the Board of Directors on the 2025 performance and the proposed operational plan for 2026;
- Report of the Board of Management on the 2025 Business and Production results and the implementation plan for 2026;
- Report of the Board of Supervisors on the 2025 activities, supervisory work and the proposed plan for 2026;

Accordingly, the business and production plan for the year 2026 is as follows:

No.	INDICATOR	UNIT	VALUE
I	Total Revenue	Million VND	412,071
II	Cost of Goods Sold	Million VND	321,273
III	Total Gross Profit	Million VND	90,797
IV	Total Selling Expenses	Million VND	4,949
	Financial Expenses	Million VND	5,120
V	Administrative Expenses	Million VND	62,822
VI	Profit Before Tax	Million VND	15,005


- Article 2.** Approval of the 2025 Audited Financial Statements (*Pursuant to Proposal No. 01/2026/TTr-DHĐCĐ dated June 29, 2026*).
- Article 3.** Approval of the Selection of the Independent Auditor for the 2026 Financial Statements (*Pursuant to Proposal No. 02/2026/TTr-DHĐCĐ dated June 29, 2026*).
- Article 4.** Approval of the profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026 (*Pursuant to Proposal No. 03/2026/TTr-DHĐCĐ dated June 29, 2026*).
- Article 5.** Approval of the remuneration for the Board of Directors and the Board of Supervisors for 2025 (*Pursuant to Proposal No. 04/2026/TTr-DHĐCĐ dated June 29, 2026*).
- Article 6.** Approval of the amendments and supplements to the Charter on Organization and Operation of the Company (*Pursuant to Proposal No. 05/2026/TTr-DHĐCĐ dated June 29, 2026*).
- Article 7.** Approval of the Dismissal for the Additional Members of the Board of Directors for the 2024 – 2029 Term (*Pursuant to Proposal No. 06/2026/TTr-DHĐCĐ and Proposal No. 07/2026/TTr-DHĐCĐ dated June 29, 2026*)
- ❖ Dismissal of Ms. Nguyen Thi Thuy and Ms. Tran Nguyen Hoang Phuc from the position of member of the Board of Directors as from the date of approval by the General Meeting of Shareholders.
 - ❖ Elect:
 - Mr. Bui Tien Thao
 - Mr. Tran Anh Tuan
 as additional members of the Board of Directors for the 2024–2029 term, effective from the date of approval by the General Meeting of Shareholders.
 - ❖ In the event that Mr. Tran Anh Tuan is elected as a member of the Board of Directors while concurrently holding the position of Chief Accountant of the Company at the time of the General Meeting, the resolution on his election as a member of the Board of Directors shall only take effect from the date the Decision dismissing him from the position of Chief Accountant becomes effective. The Board of Directors and the General Director shall be responsible for issuing the Decision on the dismissal of Mr. Tran Anh Tuan from the position of Chief Accountant and appointing a person in charge of accounting



or a replacement Chief Accountant in accordance with the Law on Accounting, no later than the date on which this Resolution is adopted.

Article 8. This Resolution shall take effect from the date of issuance. The Board of Directors, the Board of Supervisors, the Board of Management, and all relevant departments shall be responsible for implementing this Resolution.

OB. THE 2026 GENERAL MEETING OF SHAREHOLDERS

CHAIRPERSON


Thai Khắc Minh



No.: 01/2026/BB-DHDCD/MED

Hanoi, June 29, 2026

MINUTES OF MEETING

2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS

MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

Company Name: Mediplantex National Pharmaceutical Joint Stock Company
Head Office: No. 358 Giai Phong Street, Phuong Liet Ward, Hanoi City
Enterprise Registration Certificate No: 0100108430, initially issued by the Hanoi Department of Planning and Investment on April 12, 2005; 20th amendment registered on January 03, 2025
Time: 1:30 PM, June 29, 2026
Venue: No. 358 Giai Phong Street, Phuong Liet Ward, Hanoi City

The 2026 Annual General Meeting of Shareholders ("AGM" or the "General Meeting") of Mediplantex National Pharmaceutical Joint Stock Company (the "Company" or "MED") was held via an online meeting platform with electronic voting and proceeded as follows:

A. PARTICIPANTS, LEGALITY, AND VALIDITY OF THE GENERAL MEETING OF SHAREHOLDER

1. Participants:

- The members of the Board of Directors ("BOD"), the Board of Supervisors ("BOS") and the Board of Management (BOM) attending the AGM included:

Board of Directors:

- Ms. Nguyen Ngoc Xuan Trang – Chairman of the BOD
- Mr. Tran Nguyen Hoang An – Member of the BOD
- Mr. Thai Khac Minh – Independent Member of the BOD;

Board of Supervisor:

- Mr. Ho Ngoc Tuan – Head of the BOS
- Ms. Ha Thi Bich Hanh – Member of the BOS
- Ms. Do Ngoc Thuy – Member of the BOS;

Board of Management:

- Mr. Mai Nhat Thanh – General Director
- Mr. Tran Nguyen Hoang An – Deputy General Director
- Mr. Tran Anh Tuan – Chief Accountant

- Shareholders and authorized representatives of shareholders entitled to vote according to the list of shareholders as of the record date of May 28, 2026 provided by the Vietnam Securities Depository and Clearing Corporation ("VSDC") (the "Attendees").



- Representative of the Auditing firm: AASC Auditing Firm Company Limited
 - Mr. Tran Thanh Tung
- Representative of Vietnam Pharmaceutical Corporation – JSC:
 - Mr. Bui Tien Thao

2. Legality and Validity of the General Meeting:

As of the opening time of the General Meeting at **1:30 p.m. on June 29, 2026**, there were 9 attendees representing 9,378,050 shares, equivalent to 9,378,050 votes (each ordinary share carries one voting right), representing 75.5685% of the total votes of Mediplantex National Pharmaceutical Joint Stock Company.

Accordingly, pursuant to the applicable laws and the Company's Charter, the 2026 Annual General Meeting of Shareholders was duly convened, validly constituted and qualified to conduct the agenda set forth in Section I, Part B of these Minutes.

B. PROCEEDINGS OF THE GENERAL MEETING

I. Opening Procedures of the General Meeting of Shareholders:

1. **Ms. Dang Thi Hang**, on behalf of the Organizing Committee of the General Meeting, announced the purpose of the meeting and introduced the delegates.
2. **Ms. Do Ngoc Thuy**, on behalf of the Shareholder Eligibility Verification Committee, announced the shareholder attendance rate with the following result:
 - According to the attendance list as of **1:30 p.m. on June 29, 2026**, there were 9 attendees representing 9,378,050 shares, equivalent to 9,378,050 votes (each ordinary share carries one voting right), representing 75.5685% of the total votes of Mediplantex National Pharmaceutical Joint Stock Company.
 - Pursuant to the Law on Enterprises and the Company's Charter, with more than 50% of the voting shares represented at the meeting, the General Meeting of Shareholders is deemed legally and validly convened and eligible to proceed.
3. **Ms. Dang Thi Hang** introduced **Mr. Thai Khac Minh** as the Chairperson of the Meeting.
4. **Mr. Thai Khac Minh** – Chairperson of the Meeting introduced **Ms. Chu Huyen Trang** as Secretariat of the Meeting
5. **Mr. Thai Khac Minh** – Chairperson of the Meeting presented the list of the Vote Counting Committee for approval by the General Meeting.
 - Ms. Hoang Lan Huong – Head
 - Ms. Duong Thi Minh Nguyet – Member
6. **Mr. Thai Khac Minh** – Chairperson of the Meeting presented to the General Meeting The working agenda of the General Meeting. On June 25, 2026, the Board of Directors issued a Resolution supplementing the agenda with the proposal requesting the General Meeting of Shareholders to consider the dismissal of Ms. Tran Nguyen Hoang Phuc from her position as a member of the Board of Directors for the 2024–2029 term.
7. **Mr. Thai Khac Minh** – Chairperson of the Meeting presented the Working and Voting Regulations of the AGM.

108
 NG T
 PH
 TRUN
 JIPLA
 M
 H PH

8. The General Meeting unanimously approved the Voting Counting Committee, Meeting Agenda, and the Working and Voting Regulations of the AGM through electronic voting as follows:

Ms. Hoang Lan Huong – Head of the Voting Counting Committee announced the voting results as follows:

At **1:45 p.m.**, there were 16 attendees, representing 9,493,880 shares, representing 76.5019% of the total votes.

Accordingly:

- Total ballots issued: 16, representing 9,493,880 voting ballots, accounting for 100.0000% of the total shareholders attending.
- Total ballots collected: 11, representing 9,378,318 voting ballots, accounting for 98.7828% of the total shareholders attending.
- Total ballots not collected: 5, representing 115,562 voting ballots, accounting for 1.2172% of the shareholders attending.

The detailed vote counting results for each item are as follows:

Content	Number of representing voting shares and % on total number of voting ballots of shareholders attending and voting at the meeting				
	Valid	Approval	Disapproval	Abstention	Invalid
Content 01: Agenda of the 2026 Annual General Meeting of Shareholders	9,378,318	9,378,318	0	0	0
	100%	100%	0%	0%	0%
Content 02: Working and Voting Regulations of the 2026 Annual General Meeting of Shareholders	9,378,318	9,378,318	0	0	0
	100%	100%	0%	0%	0%
Content 03: The Vote Counting Committee for the 2026 Annual General Meeting of Shareholders	9,378,318	9,378,318	0	0	0
	100%	100%	0%	0%	0%

Conclusion:

- **Agenda of the 2026 Annual General Meeting of Shareholders** was approved by 100% of the total number of voting ballots of shareholders attending and voting at the meeting.
- **Working and Voting Regulations of the 2026 Annual General Meeting of Shareholders** was approved by 100% of the total number of voting ballots of shareholders attending and voting at the meeting.
- **The Vote Counting Committee for the 2026 Annual General Meeting of Shareholders** was approved by 100% of the total number of voting ballots of shareholders attending and voting at the meeting.

II. Presentation of Reports and Proposals:

1. **Mr. Thai Khac Minh** – Member of the Board of Directors, presented Report of the Board of Directors on 2025 performance results and the implementation plan for 2026 activities

2. **Mr. Mai Nhat Thanh – General Director** presented Report of the Board of Management on the 2025 business and production results and the implementation plan for 2026
3. **Mr. Ho Ngoc Tuan – Head of the Board of Supervisors** presented:
 - Report of the Board of Supervisors on the 2025 activities, supervisory work and the proposed plan for 2026
 - Proposal on Approval of the 2025 Audited Financial Statements
 - Proposal on Approval of the Selection of the Independent auditing firm for the 2025 Financial Statements
4. **Mr. Tran Nguyen Hoang An – Member of the Board of Directors** – presented the following proposals:
 - Proposal on Approval of the profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026
 - Proposal on Approval of remuneration report for the Board of Directors, Board of Supervisors for 2025 and the plan for 2026
5. **Ms. Hoang Lan Huong** presented Proposal on Approval of the Amendments and Supplements to the Charter on Organization and Operation of the Company
6. **Mr. Thai Khac Minh – Member of the Board of Directors** – presented the following proposals:
 - Proposal on Approval of the Dismissal of Ms. Nguyen Thi Thuy as a Member of the Board of Directors and the Election of an Additional Member of the Board of Directors for the 2024 – 2029 Term
 - Proposal on Approval of the Dismissal of Ms. Tran Nguyen Hoang Phuc as a Member of the Board of Directors and the Election of an Additional Member of the Board of Directors for the 2024 – 2029 Term

C. DISCUSSION OF THE REPORTS AND PROPOSALS PRESENTED AT THE GENERAL MEETING

1. **Mr. Thai Khac Minh – Chairperson of the General Meeting** chaired the discussion of the reports and proposals presented.
2. During the discussion session, attending delegates raised questions and received responses as summarized in the attached appendix.

D. THE GENERAL MEETING PROCEEDED TO VOTE AND VOTE COUNTING RESULTS

The General Meeting proceeded to vote through electronic voting, followed by the Vote Counting Committee conducted the vote counting and announced the results of 2nd voting.

Ms. Hoang Lan Huong – Head of The Vote Counting Committee announced the vote counting results as follows:

At 2:42 p.m., there were 27 attendees, representing 9,534,030 shares, representing 76.8254% of the total votes.

Accordingly:

- Total ballots issued: 27, representing 9,534,030 voting ballots, accounting for 100.0000% of the total shareholders attending.

- Total ballots collected: 21, representing 9,518,043 voting ballots, accounting for 99.8323% of the total shareholders attending.
- Total ballots not collected: 6, representing 15,987 voting ballots, accounting for 0.1677% of the shareholders attending.

The detailed vote counting results for each item are as follows:

Content	Number of representing voting shares and % on total number of voting ballots of shareholders attending and voting at the meeting				
	Valid	Approval	Disapproval	Abstention	Invalid
Content 01: Report of the Board of Directors on 2025 performance results and the implementation plan for 2026 activities	9,518,043	8,090,543	1,427,500	0	0
	100%	85.0022%	14.9978%	0%	0%
Content 02: Report of the Board of Management on the 2025 business and production results and the implementation plan for 2026	9,518,043	8,090,543	1,427,500	0	0
	100%	85.0022%	14.9978%	0%	0%
Content 03: Report of the Board of Supervisors on the 2025 activities, supervisory work and the proposed plan for 2026	9,518,043	6,756,143	2,761,900	0	0
	100%	70.9825%	29.0175%	0%	0%
Content 04: Approval of the 2025 Audited Financial Statements	9,518,043	9,518,043	0	0	0
	100%	100%	0%	0%	0%
Content 05: Approval of the Selection of the Independent auditing firm for the 2025 Financial Statements	9,518,043	9,518,043	0	0	0
	100%	100%	0%	0%	0%
Content 06: Approval of the profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026	9,518,043	5,256,131	4,259,162	2,750	0
	100%	55.2228%	44.7483%	0.0289%	0%
Content 07: Approval of remuneration report for the Board of Directors, Board of Supervisors for 2025 and the plan for 2026	9,518,043	9,515,293	0	2,750	0
	100%	99.9711%	0%	0.0289%	0%
Content 08: Approval of the Amendments and Supplements to the Charter on Organization and Operation of the Company	9,518,043	9,515,293	0	2,750	0
	100%	99.9711%	0%	0.0289%	0%
Content 09: Approval of the Dismissal of Ms. Nguyen Thi Thuy as a Member of the Board of Directors and the Election of an Additional Member of the	9,518,043	9,518,043	0	0	0
	100%	100%	0%	0%	0%

Board of Directors for the 2024 – 2029 Term.					
Content 10: Approval of the Dismissal of Ms. Tran Nguyen Hoang Phuc as a Member of the Board of Directors and the Election of an Additional Member of the Board of Directors for the 2024 – 2029 Term	9,518,043	5,325,893	2,761,900	1,430,250	0
	100%	55.9558%	29.0175%	15.0267%	0%

Conclusion:

- **Report of the Board of Directors on 2025 performance results and the implementation plan for 2026 activities** was approved by 85.0022% of the total number of voting ballots of shareholders attending and voting at the meeting.
- **Report of the Board of Management on the 2025 business and production results and the implementation plan for 2026** was approved by 85.0022% of the total number of voting ballots of shareholders attending and voting at the meeting.
- **Report of the Board of Supervisors on the 2025 activities, supervisory work and the proposed plan for 2026** was approved by 70.9825% of the total number of voting ballots of shareholders attending and voting at the meeting.
- **The 2025 Audited Financial Statements** was approved by 100% of the total number of voting ballots of shareholders attending and voting at the meeting.
- **The Selection of the Independent auditing firm for the 2025 Financial Statements** was approved by 100% of the total number of voting ballots of shareholders attending and voting at the meeting.
- **The profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026** was approved by 55.2228% of the total number of voting ballots of shareholders attending and voting at the meeting.
- **Remuneration report for the Board of Directors, Board of Supervisors for 2025 and the plan for 2026** was approved by 99.9711% of the total number of voting ballots of shareholders attending and voting at the meeting.
- **The Amendments and Supplements to the Charter on Organization and Operation of the Company** was approved by 99.9711% of the total number of voting ballots of shareholders attending and voting at the meeting.
- **The Dismissal of Ms. Nguyen Thi Thuy as a Member of the Board of Directors and the Election of an Additional Member of the Board of Directors for the 2024 – 2029 Term** was approved by 100% of the total number of voting ballots of shareholders attending and voting at the meeting.
- **The Dismissal of Ms. Tran Nguyen Hoang Phuc as a Member of the Board of Directors and the Election of an Additional Member of the Board of Directors for the 2024 – 2029 Term** was approved by 55.9558% of the total number of voting ballots of shareholders attending and voting at the meeting.

E. FINALIZATION OF THE LIST OF CANDIDATES FOR THE ADDITIONAL ELECTION OF BOARD MEMBERS

1. **Mr. Thai Khac Minh – Chairperson of the Meeting** announced that the nomination process had been completed and the final list of candidates was as follows:
 1. Mr. Bui Tien Thao
 2. Mr. Tran Anh Tuan
 3. Ms. Tran Nguyen Hoang Phuc
2. The General Meeting proceeded with the election, and the Vote Counting Committee announced the election results

At **3:02 p.m.**, there were 28 attendees, representing 9,535,905 shares, representing 76.8405% of the total votes. Accordingly:

- Total ballots issued: 28, representing 9,535,905 voting ballots, accounting for 100% of the total shareholders attending.
- Total ballots collected: 19, representing 9,516,243 voting ballots, accounting for 99.7938% of the total shareholders attending.
 - + Total valid ballots: 19, representing 9,516,243 voting ballots, accounting for 100% of the total shareholders attending and voting.
 - + Total invalid ballots: 0, representing 0 voting ballots, accounting for 0% of the total shareholders attending and voting.
- Total ballots not collected: 9, representing 19,662 voting ballots, accounting for 0.2062% of the shareholders attending.

Election Vote Counting Results:

No.	Full name	Number of votes received	% on total number of voting ballots of shareholders attending and voting
1	Bui Tien Thao	6,504,847	68.3552%
2	Tran Anh Tuan	6,996,054	73.5170%
3	Tran Nguyen Hoang Phuc	5,531,585	58.1278%

Accordingly, **Mr. Bui Tien Thao and Mr. Tran Anh Tuan** were elected to the Board of Directors.

F. APPROVAL OF THE MINUTES AND RESOLUTIONS OF THE GENERAL MEETING OF SHAREHOLDERS

1. **Ms. Chu Huyen Trang – Secretariat** – presented the Minutes and the Resolutions of the 2026 General Meeting of Shareholders to the assembly.
2. The General Meeting voted and unanimously approved the Minutes and Resolutions through electronic voting as follows:

Ms. Hoang Lan Huong – Head of the Voting Counting Committee announced the voting results as follows:

At **3:41 p.m.**, there were 28 attendees, representing 9,535,905 shares, representing 76.8405% of the total votes.

Accordingly:

- Total ballots issued: 28, representing 9,535,905 voting ballots, accounting for 100.0000% of the total shareholders attending.

- Total ballots collected: 22, representing 9,520,268 voting ballots, accounting for 99.8360% of the total shareholders attending.
- Total ballots not collected: 6, representing 15,637 voting ballots, accounting for 0.1640% of the shareholders attending.

The detailed vote counting results for each item are as follows:

Content	Number of representing voting shares and % on total number of voting ballots of shareholders attending and voting at the meeting				
	Valid	Approval	Disapproval	Abstention	Invalid
Content 01: Resolution of the 2026 Annual General Meeting of Shareholders	9,520,268	9,520,268	0	0	0
	100%	100%	0%	0%	0%
Content 02: Meeting Minutes of the 2026 Annual General Meeting of Shareholders	9,520,268	9,520,268	0	0	0
	100%	100%	0%	0%	0%

Conclusion:

- **Resolution of the 2026 Annual General Meeting of Shareholders** was approved by 100% of the total number of voting ballots of shareholders attending and voting at the meeting.
- **Meeting Minutes of the 2026 Annual General Meeting of Shareholders** was approved by 100% of the total number of voting ballots of shareholders attending and voting at the meeting.

The 2026 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company was concluded at 3:45 p.m on the same day.

SECRETARIAT



CHU HUYEN TRANG

CHAIRPERSON



THAI KHAC MINH



**APPENDIX. DISCUSSIONS AT 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
 MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY**

No.	Shareholder full name	Discussion Opinion	Company's Response
1	Mr. Bui Tien Long	<p>Regarding the profit distribution plan, the proposed dividend payout ratio for 2026 is 0% with the reason: supplementing working capital and making payment for site clearance compensation relating to the EU-GMP Pharmaceutical Manufacturing Plant Project at Hoa Lac Hi-Tech Park. To my knowledge, this project has been suspended for several years, and shareholders have not been provided with any information or documentation regarding its progress. Therefore, I request the Board of Directors to clarify the implementation status of this project.</p>	<p>Mr. Ho Ngoc Tuan, Head of the GMP-EU Plant Project Department, who was authorized by the Board of Directors to respond to shareholders, provided the following information: - The project is currently suspended. The Company is focusing on completing the legal procedures required to obtain the Certificate of Land Use Rights, with the objective of facilitating access to bank financing. - Upon obtaining the Certificate of Land Use Rights, the project will have sufficient legal basis with respect to the assets invested and formed on the land. Banks will be able to appraise the value of the investments made on the land, thereby facilitating the Company's access to credit institutions and enabling the arrangement of funding to continue the implementation of the project. The progress and plan for continuing the implementation of the project in the coming period will be reported by the Board of Directors and the Board of Management to shareholders after the funding arrangements have been completed</p>
2	Mr. Bui Tien Thao – Authorized Representative of Vietnam National	<p>The challenges presented by the Board of Management in its Report are well-founded and should be duly considered in the formulation of the Company's</p>	<p>The Board of Directors and the Executive Management acknowledged the comments of Vietnam National Pharmaceutical Corporation and committed to implementing the above</p>



No.	Shareholder full name	Discussion Opinion	Company's Response
	<p>Pharmaceutical Corporation – JSC (Vinapharm) managing its capital contribution in Mediplantex National Pharmaceutical Joint Stock Company</p>	<p>business plan. However, it is recommended that the Company's Representative propose that the Company: Develop more specific and feasible measures to control costs, improve profit margins, optimize the product portfolio, enhance operational efficiency, and make effective use of existing resources in order to achieve sustainable growth consistent with the Company's potential and market position.</p> <p>Review and reassess the assumptions underlying the business plan, and consider adjusting the target for profit before tax to better align with projected revenue growth and the objective of improving operating efficiency.</p>	<p>recommendations in order to maximize the interests of the Company.</p>